Anti-ptgfrn monoclonal antibody and use thereof
The anti-PTGFRN monoclonal antibody addresses the limitations of existing diagnostic methods by specifically targeting PTGFRN on hepatocellular carcinoma cells, including those with EMT phenotype, enhancing detection accuracy and treatment efficacy.
Patent Information
- Application Number
- PCT/KR2024/006210
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-08
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for diagnosing and monitoring hepatocellular carcinoma, such as serum biomarker detection and imaging, have limitations in accuracy and sensitivity, and existing markers like EpCAM are not effective in detecting cancer cells that have undergone epithelial-mesenchymal transition, leading to poor detection rates and inadequate treatment outcomes.
Development of an anti-PTGFRN monoclonal antibody (63-D7) that specifically binds to PTGFRN, a surface marker on cancer cells, allowing for the detection and isolation of circulating cancer cells, including those in a hybrid epithelial/mesenchymal state, which are associated with metastasis and recurrence.
The anti-PTGFRN monoclonal antibody effectively detects a high percentage of cancer cells in hepatocellular carcinoma patients, including those with EMT phenotype, improving diagnostic accuracy and potentially inhibiting cancer metastasis by targeting PTGFRN, thereby enhancing treatment outcomes.
Smart Images

Figure KR2024006210_14112024_PF_FP_ABST
Abstract
Description
Anti-PTGFRN monoclonal antibody and its use
[0001] The present invention relates to an anti-PTGFRN monoclonal antibody for determining the level of blood cancer cells, treating or preventing cancer, predicting the prognosis of cancer metastasis, and screening for anticancer drugs.
[0002]
[0003] Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers and is the third leading cause of cancer-related deaths. The primary treatments for HCC include surgical resection, local resection for early-stage HCC, or liver transplantation. However, most patients are diagnosed with advanced disease at the time of initial HCC diagnosis, and survival is limited to palliative treatments such as transarterial chemoembolization, systemic therapy with tyrosine kinase inhibitors, and selective internal radiation therapy. However, HCC has a high recurrence rate, making treatment outcomes unsatisfactory. Currently, the diagnosis and monitoring of HCC primarily rely on serum biomarker detection, pathological examination, and imaging analysis. However, the diagnostic sensitivity of the commonly used serum marker, AFP, is only 58-66%. When AFP is combined with another marker, des-gamma-carboxy-prothrombin (DCP), the diagnostic sensitivity is only around 82%. Furthermore, imaging and pathological examinations have limitations in diagnostic accuracy and sensitivity, necessitating better approaches for the diagnosis and monitoring of hepatocellular carcinoma.
[0004] Circulating tumor cells (CTCs) are cancer cells found in the peripheral blood of cancer patients and travel through the bloodstream. Metastasis can be a direct cause of the majority of cancer-related deaths, and circulating tumor cells are the seeds of this metastasis, spreading cancer. They form homo- and hetero-clusters to evade immune cells and internal and external inhibitory signals to metastasize. Their expression levels are correlated with cancer survival rates. Since an increase in the number of circulating tumor cells in the peripheral blood indicates the progression of metastasis in cancer patients, methods have been developed to use circulating tumor cells as a diagnostic marker for cancer metastasis. Furthermore, circulating tumor cells are associated with a poor prognosis in cancer patients. Unlike biopsy, liquid biopsy allows for the simple detection of circulating tumor cells, offering a novel alternative for cancer diagnosis. Animal models have shown that circulating cancer cells spread from the primary tumor through the bloodstream from the early stages of cancer. In hepatocellular carcinoma, circulating cancer cells can be detected in the early stages, before metastasis has been observed. Therefore, methods for early detection and management of hepatocellular carcinoma through circulating cancer cell diagnosis have been proposed. However, circulating cancer cells are very rare, making efficient isolation from the blood challenging. Furthermore, it is believed that different circulating cancer cells emerge and migrate from various cancer types, making accurate detection and isolation of circulating cancer cells, which vary in size and number, challenging.To date, blood cancer cells have been separated and studied using a cell search system using EpCAM, a microfluidics system based on cell size and physical characteristics, and a flow cytometer. However, due to the diversity of blood cancer cells, there are blood cancer cells similar in size to white blood cells, and there are cells that cannot be separated due to physical characteristics. Therefore, it is important to separate blood cancer cells using a surface biomarker that reflects the characteristics of hepatocellular carcinoma.
[0005] The only marker currently approved by the US FDA for isolating circulating cancer cells from various cancers is Epithelial Cell Adhesion Molecule (EpCAM), which is of epithelial origin. However, despite the liver being an epithelial-derived organ, the majority of hepatocytes and hepatocellular carcinomas are EpCAM-negative. In fact, only 15-30% of hepatocellular carcinoma tissues are EpCAM-positive when stained with an immunohistochemical method. Therefore, a method was used to detect circulating cancer cells positive for the asialoglycoprotein receptor (ASGPR), which binds to asialofetuin, a marker different from EpCAM in hepatocellular carcinoma. In 85 hepatocellular carcinoma patients, the proportion of circulating cancer cells detected at least one per 5 ml of blood was detected in 69 patients, or approximately 81%. However, there was no clear correlation between the number of circulating cancer cells detected by ASGPR and the stage of hepatocellular carcinoma metastasis. Meanwhile, research results showing that EpCAM is a marker of liver cancer stem cells that induce metastasis of hepatocellular carcinoma or induce relapse after treatment have raised interest in EpCAM-positive blood cancer cells that exhibit stem cell characteristics in the field of hepatocellular carcinoma.
[0006] Fudan University in China found that among 123 patients with hepatocellular carcinoma before surgery, only 51 patients (41%) had more than 2 EpCAM-positive circulating cancer cells per 7.5 ml of blood. However, the rate of recurrence after surgery was significantly higher than that of patients with less than 2 circulating cancer cells, at 87.5% versus 15.5%. In another study, among 59 patients with hepatocellular carcinoma, only 18 patients (31%) had more than 1 EpCAM-positive circulating cancer cell per 7.5 ml of blood. However, EpCAM-positive circulating cancer cells were observed in intermediate or higher stages and were closely related to the survival rate. In another study, using an EpCAM-based blood cancer cell detection method, only 14 patients (28%) had more than one blood cancer cell per 7.5 ml of blood in 50 hepatocellular carcinoma patients. Overall, the EpCAM-based blood cancer cell detection method showed a detection rate of less than 50%. This is because EpCAM expression decreases due to epithelial-mesenchymal transition, which occurs during cancer metastasis, and is a fundamental limitation of the EpCAM-based blood cancer cell detection method.
[0007] Epithelial-mesenchymal transition (EMT) refers to the entire process by which adherent epithelial cancer cells transition into mesenchymal cancer cells with migratory and invasive properties. During the EMT process, epithelial cell markers may be downregulated, so if circulating cancer cells are detected solely by epithelial cell markers, most circulating cancer cells may not be detected. In fact, when EpCAM is used as a marker to detect circulating cancer cells, only about 50-70% of all circulating cancer cells can be detected in lung cancer, breast cancer, cervical cancer, and nasopharyngeal cancer, and in the case of liver cancer, only 25% of the total circulating cancer cells can be detected. A study of circulating cancer cells with mixed and mesenchymal markers in hepatocellular carcinoma (HCCs) revealed that patients with a higher number of circulating cancer cells had stronger invasive potential and that these patients had advanced clinical stages. Furthermore, a study of circulating cancer cells and circulating cancer cell clusters collected from the peripheral blood of 214 HCC patients revealed that circulating cancer cell clusters were closely associated with overall survival (OS) and progression-free survival (PFS), indicating a poor prognosis.
[0008] Meanwhile, recent research has shown that EMT can be reversible and transient, and that partial EMT occurs rather than cells undergoing complete EMT to become mesenchymal. In fact, most circulating cancer cells are known to possess a hybrid epithelial / mesenchymal state or a partial phenotype, an intermediate form possessing both epithelial and mesenchymal characteristics. These cells are known to cluster and have immune-evading capabilities, allowing them to evade the host immune system. Therefore, to detect all circulating cancer cells in a patient, it is necessary to develop markers that can detect not only epithelial circulating cancer cells, but also circulating cancer cells exhibiting an EMT phenotype, circulating cancer cells exhibiting partial EMT, and entirely new types of circulating cancer cells.
[0009] PTGFRN (Prostaglandin F2 Receptor Negative Regulator, EWI-F, CD9P-1, CD315) is a type I transmembrane protein of the immunoglobulin superfamily that negatively affects the prostaglandin F2 receptor. PTGFRN is a component of the Tetraspanin-Enriched Microdomain (TEM), which is composed of tetraspanins, integrins, signaling enzymes, and proteoglycans, and interacts with tetraspanin proteins such as CD9 and CD81. PTGFRN is highly expressed as a structural protein in exosomes, and its function in separating exosomes is being studied. In addition, PTGFRN expression is involved in muscle cell regeneration, glioma growth, and metastasis. PTGFRN is a molecule that is up-regulated in many cancer cells, including gliomas, and is known to be overexpressed in glioblastoma multiforme (GBM), a malignant brain tumor, where it promotes cell growth and radioresistance through PI3K-AKT signaling.
[0010] The present inventors have developed 70 monoclonal antibodies that bind to the surface of human embryonic stem cells, and one of them, 63-D7, binds well to the surface of various human cancer cells, including human embryonic stem cells, embryonic cancer cells, and liver cancer cells, but does not bind to normal cells such as human peripheral blood mononuclear cells (PBMC), fetal lung fibroblasts (MRC5), and normal hepatocytes. In this invention, after discovering that the 63-D7 antibody recognizes circulating cancer cells in liver cancer patients, we identified its target molecule as PTGFRN. 63-D7 recognized PTGFRN in liver cancer, lung cancer, colon cancer, thyroid cancer, and pancreatic cancer cells. In experiments on viability, invasion, and migration using liver cancer cells, we confirmed that suppressing PTGFRN gene expression inhibits the clonal survival, migration, and invasion of cancer cells, thereby inhibiting cancer metastasis. In addition, in an analysis of 95 patients with liver cancer, the 63-D7 antibody was able to detect circulating cancer cells in 92 patients (97%, 92 / 95), and the detectable rate was observed to increase further in patients with metastasis or recurrence. In addition, PTGFRN recognized by 63-D7 was highly co-expressed with B7-H3 (57.6%), MVP (31.9%), TGFβR1 (51.8%), PD-L1 (37.8%), PD-L2 (17.5%), and CD47 (38.1%), which are associated with drug resistance and immune evasion in circulating cancer cells, showing that the expression of PTGFRN is closely related to metastasis or recurrence, and suggesting that these molecules can induce immune evasion of cancer cells. In addition, we revealed that 63-D7 is an antibody that induces internalization in liver cancer cells and pancreatic cancer cells, and in fact, through this characteristic, we suggest that 63-D7 can be developed as a cancer treatment agent in the future by inducing liver cancer cell death using an antibody-drug conjugate (ADC).Furthermore, we confirmed that 63-D7 treatment increased the invasiveness of liver cancer cells, suggesting that the 63-D7 antibody itself is an agonistic antibody that promotes the migration and invasiveness of liver cancer cells. By utilizing these properties, the 63-D7 antibody is expected to be applied to promote cancer cell migration in primary tumors, thereby preventing the development of early-stage primary tumors or interfering with their growth.
[0011]
[0012] The present invention aims to provide a use of PTGFRN as a surface molecular marker of cancer cells.
[0013] The present invention aims to provide a monoclonal antibody 63-D7 that specifically binds to PTGFRN.
[0014] The present invention aims to provide the use of monoclonal antibody 63-D7 as an agonistic antibody against PTGFRN that increases motility and invasiveness in cancer cells.
[0015] The present invention aims to provide a use of PTGFRN as a surface molecular marker of blood cancer cells.
[0016] Another object of the present invention is to provide a use of the monoclonal antibody 63-D7 as a substance that specifically binds to PTGFRN to isolate, purify or detect the PTGFRN protein.
[0017]
[0018] 1. An anti-PTGFRN monoclonal antibody comprising a heavy chain variable region comprising HCDR1 consisting of the amino acid sequence of SEQ ID NO: 3, HCDR2 consisting of the amino acid sequence of SEQ ID NO: 4, and HCDR3 consisting of the amino acid sequence of SEQ ID NO: 5; and a light chain variable region comprising LCDR1 consisting of the amino acid sequence of SEQ ID NO: 6, LCDR2 consisting of the amino acid sequence of SEQ ID NO: 7, and LCDR3 consisting of the amino acid sequence of SEQ ID NO: 8.
[0019] 2. In the above 1, the heavy chain variable region is an anti-PTGFRN monoclonal antibody comprising the amino acid sequence of sequence number 1.
[0020] 3. An anti-PTGFRN monoclonal antibody according to claim 1, wherein the light chain variable region comprises the amino acid sequence of sequence number 2.
[0021] 4. An antibody-drug conjugate in which a drug is conjugated to any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0022] 5. A pharmaceutical composition for treating or preventing cancer, comprising any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0023] 6. In the above 5, the cancer is selected from the group consisting of brain and spinal tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophageal cancer, stomach cancer, colon cancer, liver cancer, thyroid cancer, pancreatic cancer, biliary tract cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, germ cell tumor, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma, neuroblastoma, glioblastoma, and skin cancer, a pharmaceutical composition for treating or preventing cancer.
[0024] 7. A hybridoma producing any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0025] 8. A composition for detecting PTGFRN comprising any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0026] 9. A method for providing information for diagnosing cancer, comprising the step of treating a sample isolated from an individual with any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0027] 10. A method for providing information necessary for determining the level of cancer cells in blood, comprising the step of treating a sample isolated from an individual with any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0028] 11. A method for providing information necessary for determining the level of blood cancer cells, wherein the sample is selected from the group consisting of blood, plasma, bone marrow, lymph, saliva, tears, urine, mucosal fluid, and amniotic fluid in the above 10.
[0029] 12. A method for providing information necessary for determining the level of cancer cells in blood, further comprising a step of treating a sample with a substance that specifically binds to EpCAM in the above 10.
[0030] 13. A method for providing information necessary for determining the level of cancer cells in blood, wherein the substance specifically binding to EpCAM in the above 12 is an anti-EpCAM antibody or an antigen-binding fragment thereof.
[0031] 14. In the above 10, a method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells are blood cancer cells that have undergone epithelial-mesenchymal transition or are undergoing epithelial-mesenchymal transition.
[0032] 15. In the above 10, a method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells are not epithelial cells or mesenchymal cells.
[0033] 16. In the above 10, the blood cancer cells are blood cancer cells in the blood of a patient with liver cancer, lung cancer, colon cancer, thyroid cancer, pancreatic cancer, malignant melanoma, breast cancer, neuroblastoma or glioblastoma, a method for providing information necessary for determining the level of blood cancer cells.
[0034] 17. A method for providing information necessary for determining the level of blood cancer cells, wherein blood cancer cells in the above 10 more express B7-H3 (CD276) protein.
[0035] 18. A method for providing information necessary for predicting the prognosis of cancer metastasis, comprising a step of detecting PTGFRN by treating a sample isolated from an individual with any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0036] 19. A method for providing information necessary for predicting the prognosis of cancer metastasis, further comprising a step of providing information that if the level of detected PTGFRN is higher than that of the control group, the prognosis of cancer metastasis is worse than that of the control group.
[0037] 20. A method for screening the efficacy of an anticancer drug, comprising the step of detecting PTGFRN by treating a sample isolated from a patient administered an anticancer drug with any one of the above 1 to 3 anti-PTGFRN monoclonal antibodies.
[0038] 21. A method for screening the efficacy of an anticancer drug, further comprising a step of predicting that the anticancer drug has a better anti-cancer metastasis inhibition efficacy than the control group if the level of PTGFRN detected in the above 20 is lower than that of the control group.
[0039] 22. A composition for detecting blood cancer cells, comprising a substance that binds to PTGFRN.
[0040]
[0041] The anti-PTGFRN monoclonal antibody 63-D7 of the present invention can be used for determining the level of blood cancer cells, treating or preventing cancer, predicting the prognosis of cancer metastasis, and screening for anticancer drugs.
[0042] The anti-PTGFRN monoclonal antibody of the present invention can specifically bind to PTGFRN on the surface of various cancer cells, including liver cancer.
[0043] Using the anti-PTGFRN monoclonal antibody of the present invention, various antibody-drug conjugates can be developed and used as anticancer agents.
[0044] By utilizing the fact that the anti-PTGFRN monoclonal antibody of the present invention stimulates PTGFRN to increase the mobility and invasiveness of cancer cells, the anti-PTGFRN monoclonal antibody of the present invention can be used to prevent and suppress the cancer growth of primary cancer by promoting the migration of primary cancer cells.
[0045] The anti-PTGFRN monoclonal antibody of the present invention can detect blood cancer cells that are neither epithelial nor mesenchymal.
[0046] The anti-PTGFRN monoclonal antibody of the present invention can partially detect circulating cancer cells that have undergone epithelial-mesenchymal transition.
[0047] The anti-PTGFRN monoclonal antibody of the present invention can detect blood cancer cells with high efficiency in liver cancer patients.
[0048] Blood cancer cells detected by the anti-PTGFRN monoclonal antibody of the present invention are measured at a higher level in patients with secondary metastatic cancer than in patients with primary cancer, so that the stage of cancer can be determined through the anti-PTGFRN monoclonal antibody of the present invention.
[0049] The anti-PTGFRN monoclonal antibody of the present invention can be internalized into cancer cells, thereby effectively delivering the drug into cancer cells.
[0050] The present invention also provides PTGFRN as a surface marker of blood cancer cells.
[0051] Anti-PTGFRN monoclonal antibodies can be used for isolation, purification, and detection of PTGFRN protein through highly specific binding to PTGFRN protein.
[0052] Anti-PTGFRN monoclonal antibody binds to circulating cancer cells with epithelial-mesenchymal transition and partially epithelial-mesenchymal transition that express PTGFRN on their surface, allowing the detection of previously undetectable circulating cancer cells.
[0053] Anti-PTGFRN monoclonal antibodies may be useful in the diagnosis of metastatic cancer by detecting cancer cells in the blood.
[0054]
[0055] Fig. 1a is a graph showing the results of flow cytometry, showing the degree of binding of antibodies 246-D7, 247-B9 and monoclonal antibody 63-D7 of the present invention to human embryonic stem cells H9, two types of liver cancer cells (Huh7, HepG2), two types of lung cancer cells (A549, NCI-H358), and peripheral blood mononuclear cells (PBMC), respectively. Fig. 1b is a table showing the graph of Fig. 1a. Fig. 1c shows the results of immunocytochemical staining, in order to confirm the detection of cancer cells in the blood, double staining was performed using monoclonal antibodies 63-D7, 246-D7, 247-B9 labeled with biotin and CD45 antibody in the blood of eight liver cancer patients and one normal person, respectively, and the nuclei were stained with DAPI, and the Merge of these was shown. Figure 1d shows the results of Figure 1c in a table.
[0056] Figure 2 shows the results of flow cytometry, which shows that the monoclonal antibody 63-D7 of the present invention strongly binds to various cancer cells (SK-Hep1, A549, NCI-H358, NCI-H460, NCI-H1703, NCI-H23, Colo205, HCT116, SNU790, 8505C, BxPC3, A375, MCF-7, MDA-MB-435, SH-SY5Y, U87-MG) including human pluripotent stem cells (H9), human embryonic carcinoma cells (NT2 / D1) and hepatoma cells (Huh7, HepG2, SNU387, SNU449) and human embryonic kidney cells (HEK293FT), but weakly binds to bone marrow-derived mesenchymal stem cells (BM-MSC) and human dermal fibroblasts (HDF), and human peripheral blood mononuclear cells (PBM). It shows no binding to blood mononuclear cells (PBMCs), human fetal lung fibroblasts (MRC5), dental pulp cells (DPCs), and normal hepatocytes. The solid line represents monoclonal antibody 63-D7, and the shaded background represents a negative control containing only the secondary antibody.
[0057] Figure 3a shows the results of immunoprecipitation of proteins using monoclonal antibody 63-D7 from cell lysates of NT-2 / D1 human embryonic cancer stem cells (NT-2 / D1-biotin) whose cell surface was labeled with biotin, separation by 10% SDS-PAGE, Western blotting, transfer to a nitrocellulose membrane, and analysis by reaction with streptavidin-HRP (SA-HRP). The same experiment performed without adding antibody (No Ab) was used as a negative control (Con). The arrow indicates the protein immunoprecipitated by 63-D7. Figure 3b shows the results of separating immunoprecipitated proteins in the same manner as in Figure 3a through 10% SDS-PAGE, and staining the polyacrylamide gel with PageBlue. 1X means that 3 mg of cell lysate was used, and 3x means that three times that amount was used. Afterwards, the protein within the dotted box in Fig. 3b was extracted and subjected to LC-MS / MS. Fig. 3c shows the results of LC-MS / MS analysis of the protein recovered after immunoprecipitation with monoclonal antibody 63-D7 in Fig. 3b, with the portion of the amino acid sequence of the 63-D7 antigen that matches the amino acid sequence of the PTGFRN protein underlined.
[0058] Figure 4a shows the results of Western blotting using mouse α-PTGFRN antibody after immunoprecipitation of proteins from biotin-labeled human non-small cell lung cancer A549 cell lysates using mouse anti-PTGFRN monoclonal antibody (α-PTGFRN) and mouse 63-D7 monoclonal antibody, respectively, and a negative control protein without antibody (No Ab), separated by 10% SDS-PAGE. Figure 4b shows the results of analysis using streptavidin-HRP (SA-HRP) after removing the nitrocellulose membrane of Figure 4a with a signal-removing solution, confirming that PTRFRN is a cell surface molecule recognized by 63-D7. Figure 4c shows the results of immunoprecipitation and Western blotting of the cell lysate with a known mouse anti-FLAG monoclonal antibody (α-FLAG), a known mouse anti-PTGFRN monoclonal antibody (α-PTGFRN), and monoclonal antibody 63-D7 to reconfirm that the antigen of monoclonal antibody 63-D7 is PTGFRN. WB indicates Western blot.
[0059] Figure 5a shows the results of a PTGFRN knockdown experiment performed in hepatoma cell lines Huh7 and SNU449. The expression of PTGFRN mRNA was analyzed by qPCR in hepatoma cells treated with a negative control siRNA (siCon) and two types of siRNA against PTGFRN (siPTGFRN#1 and siPTGFRN#2), respectively, to perform knockdown. Figure 5b shows the results of flow cytometry to determine the extent of binding of a mouse PTGFRN monoclonal antibody (α-PTGFRN) to PTGFRN on the surface of knocked-down Huh7 and SNU449 cells. The solid line represents the monoclonal antibody, and the shaded background represents the negative control (isotype) data containing only the secondary antibody. Figure 5c is a graph statistically analyzing Figure 5b. Figure 5d shows the results of measuring the clonogenic survival of cancer cells in PTGFRN knockdown Huh7 and SNU449 cells, staining the surviving cell clones with crystal violet eight days after cell inoculation. Figure 5e is a graph statistically analyzing Figure 5d, where * indicates a p value of p<0.05.
[0060] Figure 6a shows the results of a PTGFRN knockdown experiment performed in hepatoma cell lines Huh7 and SNU449. After transfecting human embryonic carcinoma cells HEK293FT with a negative control scrambled shRNA (shScramble) or shRNAs against two PTGFRNs (shPTGFRN#1, shPTGFRN#2), lentiviruses were harvested and treated to Huh7 and SNU449 hepatoma cells to perform knockdown, and PTGFRN protein expression was confirmed by Western blotting. Figure 6b shows the results of flow cytometry analysis showing a decrease in PTGFRN expression in Huh7 and SNU449 hepatoma cells. Figure 6c is a graph showing a statistical analysis of Figure 6b. Figure 6d shows the results of measuring cancer cell clonogenic survival in SNU449 knocked down with shPTGFRN#1. Cell clones that survived 8 days after cell inoculation were stained with crystal violet, and shScramble is the control. Figure 6e shows the results of statistical analysis of Figure 6d, where *** indicates p<0.005 compared to the control group (shScramble). Figure 6f shows the results of measuring cancer cell clonogenic survival in SNU449 knocked down with shPTGFRN#2. Figure 6g shows the results of statistical analysis of Figure 6f, where *** indicates p<0.005.
[0061] Figure 7a shows the results of measuring the degree of migration of liver cancer cells using a negative control shRNA (shScramble) or shRNAs against two types of PTGFRN (shPTGFRN#1, shPTGFRN#2). PTGFRN knockdown liver cancer cells Huh7 and SNU449 were dispensed into a 24-well transwell chamber and cultured for two days. The cells that migrated to the lower chamber were stained with crystal violet and photographed. Figure 7b is a graph that statistically processed the experiment in Figure 7a by repeating it three times. *** indicates p<0.001, ** indicates p<0.01, and * indicates p<0.05. Figure 7c shows the results of measuring the invasiveness of cancer cells using a negative control shRNA (shscramble) or shRNAs against two types of PTGFRN (shPTGFRN#1, shPTGFRN#2). PTGFRN knockdown hepatoma cells Huh7 and SNU449 were seeded on Matrigel-coated transwell chambers and cultured for two days. The cells that had invaded the lower layer were stained with crystal violet and photographed. Figure 7d is a graph showing the statistical analysis of the experiment in Figure 7c repeated three times. *** indicates p<0.001, ** indicates p<0.01, and * indicates p<0.05.
[0062] Figure 8a is a photograph of attached liver cancer cells observed under a microscope after knockdown was performed by treating liver cancer cells with a negative control scrambled shRNA (shScramble) or two shRNAs for PTGFRN (shPTGFRN#1, shPTGFRN#2) in the liver cancer cell line Huh7, and the degree of cell adhesion was analyzed by reacting the PTGFRN knockdown liver cancer cells to a 12-well cell culture plate coated with Matrigel, CollagenⅠ, CollagenⅣ, and gelatin. Figure 8b is a graph showing the degree of cell binding statistically processed by analyzing the microscope photographs with Image J after repeating the experiment in Figure 8a. *** indicates p<0.001, ** indicates p<0.01, * indicates p<0.05, and ns indicates no statistical significance. Figure 8c is a photograph of attached liver cancer cells observed under a microscope after knockdown was performed by treating liver cancer cells with a negative control scrambled shRNA (shScramble) or two types of shRNA against PTGFRN (shPTGFRN#1, shPTGFRN#2) in the liver cancer cell line SNU449, and then reacting the PTGFRN knockdown liver cancer cells to a 12-well cell culture plate coated with Matrigel, CollagenⅠ, CollagenⅣ, and gelatin to analyze the degree of cell attachment. Figure 8d is a graph showing the degree of cell attachment statistically processed by analyzing the microscope photographs with Image J after repeating the experiment in Figure 8c. *** indicates p<0.001, ** indicates p<0.01, * indicates p<0.05, and ns indicates no statistical significance.
[0063] Figure 9a shows the results of measuring the immune evasion ability of PTGFRN knockdown liver cancer cells against NK cells. Knockdown was performed by treating SNU449 liver cancer cells with a negative control scrambled shRNA (shscramble) or shPTGFRN#2, and the SNU449 cells that remained after co-culture of the PTGFRN knockdown liver cancer cells with NK92 were stained with crystal violet. 1:1, 2.5:1, and 5:1 represent the ratios (E:T ratios) of NK92, which are effector cells, and SNU449, which are target cells. Figure 9b is a graph showing the quantification by measuring the absorbance at OD540 after thawing the cells in Figure 9a. Figure 9c is a graph showing the degree of cell death by expressing the OD540 results measured in Figure 9b as the E:T ratio.
[0064] Figure 10 shows the results of Western blot analysis of changes in the expression of B7-H3, FAK, Src proteins and phosphorylated p-FAK (Y397), p-Src (Y416) proteins in PTGFRN knockdown hepatoma cells Huh7 and SNU449 using negative control shRNA (shScramble) or shRNA for two types of PTGFRN (shPTGFRN#1, shPTGFRN#2). GAPDH is the control, and the numbers are quantified using Image J.
[0065] Figure 11a shows the results of immunoprecipitation with mouse anti-FLAG, rabbit anti-myc, and 63-D7 antibodies and Western blotting with anti-FLAG and anti-myc antibodies to confirm the cis interaction of the same PTGFRN within a single cell after co-transfection of HEK293FT cells with pcDNA3.1(+)PTGFRN-FLAG vector and pcDNA3.1(+)PTGFRN-myc vector. No Ab is the control, and the arrow indicates immunoprecipitated PTGFRN. Figure 11b shows the results of mixing the eluates of HEK293FT cells transfected with pcDNA3.1(+)PTGFRN-FLAG vector and pcDNA3.1(+)PTGFRN-myc vector, respectively, and immunoprecipitating them with mouse anti-FLAG, rabbit anti-myc, and 63-D7 to confirm trans-interactions between different cells, and performing Western blotting with anti-FLAG and anti-myc antibodies. No Ab is the control, and the arrow indicates immunoprecipitated PTGFRN. Figure 11c shows the immunoprecipitation of PTGFRN by SLC3A2 (CD98hc) and B7-H3 in hepatoma cells SNU449 with mouse anti-PTGFRN monoclonal antibody (α-PTGFRN), mouse anti-63-D7 monoclonal antibody, mouse anti-SLC3A2, and mouse anti-B7-H3, respectively, followed by Western blotting with α-PTGFRN, showing that PTGFRN is immunoprecipitated by SLC3A2 (CD98hc) and B7-H3. Figure 11d shows the results of co-transfecting HEK293FT cells with pcDNA3.1(+)PTGFRN-myc vector and pcDNA3.1(+)B7-H3-FLAG vector to confirm the interaction between B7-H3 and PTGFRN, followed by immunoprecipitation with anti-FLAG, anti-B7-H3, anti-myc, and 63-D7, and detection with anti-myc and anti-FLAG antibodies, confirming that they interact with each other. HC stands for immunoglobulin heavy chain. In Figures 11a to 11d, WB stands for Western blot.
[0066] Figures 12a and 12b show the results of measuring cell adhesion on a Materiel-coated plate after sorting 63-D7-positive and -negative cells using 63-D7 antibody and magnetic beads in the liver cancer cell lines Huh7 and HepG2, respectively. Figure 12c shows the results of flow cytometry analysis comparing the cancer cell binding ability of 63-D7 with that of adherent cells, which are cancer stem cell-positive markers, CD133, CD44, and EpCAM, after Huh7 was cultured as tumor cells to increase cancer stem cell potential. Figure 12d is a graph statistically analyzing Figure 12c. *** indicates p<0.005. Figure 12e is a result of measuring the clonogenic survival of 63-D7-positive and -negative cancer cells in the liver cancer cell line Huh7 sorted with 63-D7, showing the cancer stemness of cancer cells. It is a picture of cell clones that survived 8 days after cell inoculation, stained with crystal violet. Figure 12f is a picture of the statistical analysis of the results of Figure 12e. *** indicates p<0.005 compared to the control group. Figure 12g is a picture of the clonogenic survival of 63-D7-positive and -negative cancer cells in the liver cancer cell line HepG2 sorted with 63-D7. Figure 12h is a picture of the statistical analysis of the results of Figure 12g. *** indicates p<0.005 compared to the control group.
[0067] Figures 13a and 13b show the results of flow cytometry analysis of the internalization of monoclonal antibody 63-D7 into human liver cancer cells Huh7, HepG2, SNU449 and human pancreatic cancer cells SNU213 and BxPC3. In Figures 13a and 13b, the solid line is the monoclonal antibody and 63-D7 reacted at 4°C, the dotted line is the 63-D7 antibody reacted at 37°C after reacting at 4°C, and the shaded background includes only the secondary antibody. Figure 13c is a graph comparing the degree of attachment of 63-D7 on the cell surface of each cancer cell by statistically processing it as the relative average fluorescence intensity by repeating the same experiment as Figure 13a three times. **** indicates p<0.001, *** indicates p<0.005, ** indicates p<0.01, and * indicates p<0.05. Figure 13d is a graph comparing the degree of attachment of 63-D7 to the cell surface of each cancer cell by statistically processing it as a relative average fluorescence intensity by repeating the same experiment as Figure 13b three times. **** indicates p<0.001, *** indicates p<0.005, ** indicates p<0.01, and * indicates p<0.05.
[0068] Figures 14a and 14b show the results of measuring the cell viability of Huh7 cells treated with 63-D7 or mouse IgG isotype antibodies. After Huh7 cells were treated with 63-D7 or mouse isotype antibodies at concentrations of 0 nM to 100 nM, respectively, Figure 14a shows that they were treated with α-mFc-CL-DMDM, and Figure 14b shows that they were treated with α-mFc-CL-MMAF for 48 hours, and the cell viability was measured using CCK-8. In Figures 14a and 14b, * indicates p<0.05, ** indicates p<0.01, and **** indicates p<0.001.
[0069] Fig. 15a is a diagram showing a method for detecting blood cancer cells recognized by the PTGFRN-specific monoclonal antibody 63-D7 of the present invention in the blood of a liver cancer patient, and shows a method for removing CD45-positive cells and staining the remaining cells with Dylight488-conjugated 63-D7 and another marker (antibody). Fig. 15b is a graph showing the recovery rate measured by counting the recovered Huh7 cells after adding 0, 10, 30, 50, and 100 Huh7 cells to PBMC and removing CD45-positive cells as shown in 15a. Fig. 15c shows the blood cancer cells recovered as shown in Fig. 15a, stained with Dylight649-conjugated anti-mouse IgG and Dylight488-conjugated 63-D7, and DAPI for staining the nuclei, and Merge for combining them.
[0070] Figures 16a to 16c are confocal microscopy images showing blood cancer cells double-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention and anti-MVP, anti-HSA, anti-PanCK, anti-E-cadherin, anti-EpCAM, 63-D7, anti-Vimentin, anti-Twist, and anti-ZEB1 antibodies in the blood of a liver cancer patient, and DAPI that stains the nucleus, and Merge that combines them.
[0071] Figure 17 is a graph comparing the number of all blood cancer cells (63-D7+ cells / ml) recognized by the monoclonal antibody 63-D7 of the present invention in the blood of liver cancer patients (53 primary HCC and 42 metastatic HCC) and normal people and hepatitis patients (26 non-neoplastic) through a comparison test (Kruskal-Wallis Test) among the three groups (p value <0.0001). It shows that the p-values for each group are all <0.0001, indicating that the differences among the three groups are all significant.
[0072] FIG. 18a is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-EpCAM, and anti-Vimentin antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field. FIG. 18b is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-MVP, and anti-B7-H3 antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field. BF stands for bright field.
[0073] Figure 19 is a confocal microscope image showing blood cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-TGFβR1, and anti-B7-H3 antibodies in the blood of a liver cancer patient, along with DAPI, which stains the nuclei, and a merge of these. BF stands for bright field.
[0074] FIG. 20a is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-ULBP1, and anti-B7-H3 antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field. FIG. 20b is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-MICA / B, and anti-B7-H3 antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field.
[0075] FIG. 21a is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-PD-L1, and anti-B7-H3 antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field. FIG. 21b is a confocal microscope image showing circulating cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-PD-L2, and anti-B7-H3 antibodies in the blood of a liver cancer patient, together with DAPI for staining the nuclei and a merge of these antibodies. BF stands for bright field.
[0076] Figure 22 is a confocal microscope image showing blood cancer cells triple-stained with the PTGFRN-specific monoclonal antibody 63-D7 of the present invention, anti-CD47, and anti-B7-H3 antibodies in the blood of a liver cancer patient, along with DAPI, which stains the nuclei, and a merge image of these. BF stands for bright field.
[0077] Figure 23 is a drawing showing the base sequence and amino acid sequence of the heavy chain gene variable region of the monoclonal antibody 63-D7, with the CDR (Complementarity Determining Region) that binds to the antigen indicated in bold.
[0078] Figure 24 is a drawing showing the base sequence and amino acid sequence of the light chain gene variable region of the monoclonal antibody 63-D7, with the CDR (Complementarity Determining Region) that binds to the antigen indicated in bold.
[0079]
[0080] The present invention provides an anti-PTGFRN monoclonal antibody for determining the level of blood cancer cells, treating or preventing cancer, predicting the prognosis of cancer metastasis, and screening for anticancer drugs.
[0081] The present invention provides an anti-PTGFRN monoclonal antibody comprising a heavy chain variable region comprising HCDR1 consisting of the amino acid sequence of SEQ ID NO: 3, HCDR2 consisting of the amino acid sequence of SEQ ID NO: 4, and HCDR3 consisting of the amino acid sequence of SEQ ID NO: 5; and a light chain variable region comprising LCDR1 consisting of the amino acid sequence of SEQ ID NO: 6, LCDR2 consisting of the amino acid sequence of SEQ ID NO: 7, and LCDR3 consisting of the amino acid sequence of SEQ ID NO: 8.
[0082] The term "antibody" as used herein includes a complete antibody and any antigen-binding fragment (i.e., "antigen-binding portion") or single chain thereof. An antibody refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains joined to each other by disulfide bonds, or an antigen-binding portion thereof.
[0083] Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2, and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs).
[0084] Each VH and VL is composed of three CDRs and four FRs, FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, arranged in the following order from the amino terminus to the carboxy terminus. The variable regions of the heavy and light chains include a binding domain that interacts with an antigen. The constant regions of the antibody can mediate binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0085] The CDRs included in the VH region are called heavy chain complementary determining region 1 (HCDR1), HCDR2, and HCDR3, and the CDRs included in the VL region are called light chain complementary determining region 1 (LCDR1), LCDR2, and LCDR3.
[0086] The term "antigen-binding portion" (or simply "antibody portion") of an antibody herein refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., PTGFRN). It has been determined that the antigen-binding function of an antibody can also be exerted by fragments of full-length antibodies.
[0087] Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include (i) a Fab fragment, i.e., a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, i.e., a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of one arm of an antibody; (v) a dAb fragment consisting of a VH domain [Ward et al., (1989) Nature 341:544-546]; and (vi) an isolated complementarity determining region (CDR) or (vii) a combination of two or more isolated CDRs, which may optionally be linked by a synthetic linker. Additionally, although the two domains of the Fv fragment, namely the VL and VH, are encoded by separate genes, they can be joined by a synthetic linker using recombinant methods to produce a single protein chain in which the VL and VH regions pair to form a monovalent molecule (called a single-chain Fv (scFv)). Such single-chain antibodies are also included in the term "antigen-binding portion" of an antibody. Such antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments are screened for utility in the same manner as complete antibodies. The antigen-binding portion can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of complete immunoglobulins.
[0088] The antibody herein may be a monoclonal antibody or a polyclonal antibody. The antibody may be produced using various techniques known in the art for producing humanized antibodies.
[0089] The term "monoclonal antibody" as used herein refers to an antibody that exhibits a single binding specificity and affinity for a particular epitope.
[0090] In the present disclosure, a PTGFRN-specific monoclonal antibody can be efficiently produced in a highly purified form in virtually unlimited quantities. The PTGFRN-specific monoclonal antibody can specifically bind to a specific epitope of PTGFRN.
[0091] Antibodies that bind to PTGFRN herein can be produced using viral or oncogene transformation of B cells fused to immortalized cells obtained from a non-humanized animal having a genome comprising a heavy chain transgene and a light chain transgene, phage display techniques using a library of human antibody genes, somatic cell hybridization techniques, etc. Methods for producing hybridomas in animals, including immunization protocols and isolation and fusion techniques of immunized spleen cells, for producing monoclonal antibodies are well known in the art.
[0092] Antibodies or antigen-binding fragments thereof can be labeled with radionuclides, fluorescors, enzymes, and the like.
[0093] The term "epitope" or "antigenic determining site" as used herein refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. Epitopes may be formed from adjacent amino acids or from non-adjacent amino acids juxtaposed by tertiary folding of the protein. Epitopes formed from adjacent amino acids are generally retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are generally lost upon treatment with denaturing solvents. Epitopes typically comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial conformation. Methods for determining the spatial conformation of an epitope include techniques known in the art and techniques described herein, such as x-ray crystallography and two-dimensional nuclear magnetic resonance. In this regard, reference may be made, for example, to the literature [Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, Ed. (1996)]. In a preferred embodiment, the epitope (or antigenic determinant site) functions as a conformational epitope in that no further increase in affinity for the epitope / antigenic determinant site is observed even when it is within a larger amino acid segment (e.g., a protein having a three-dimensional structure).
[0094] The term "isotype" as used herein refers to the antibody class (e.g., IgM or IgG1) encoded by the heavy chain constant region genes. In one embodiment, the monoclonal antibody of the invention is of the IgG1 isotype.
[0095] The present invention manufactures a monoclonal antibody that binds to the surface of human embryonic stem cells, and among the manufactured antibodies, the antigen of monoclonal antibody 63-D7 that binds to the surface of human embryonic stem cells, embryonic cancer cells, and various cancer cells, but does not bind to normal cells such as human peripheral mononuclear cells or human hepatocytes was searched.
[0096] In the present invention, it was revealed that the 63-D7 monoclonal antibody recognizes the cell surface protein PTGFRN (Prostaglandin F2 Receptor Negative Regulator, CD315). In addition, it was confirmed that PTGFRN recognized by the 63-D7 monoclonal antibody is expressed in cell lines such as liver cancer, lung cancer, colon cancer, pancreatic cancer, and thyroid cancer.
[0097] In the present invention, the results of experiments on 95 patients with hepatocellular carcinoma confirmed that the 63-D7 monoclonal antibody can detect circulating cancer cells with an efficiency of 97%. Since the 63-D7 antibody is co-expressed with the EMT marker Vimentin at a rate of approximately 53% in primary HCC and approximately 28% in secondary HCC, it was confirmed that the 63-D7 antibody can be used to detect circulating cancer cells showing an EMT phenotype. In addition, circulating cancer cells recognized by 63-D7 can also detect intermediate circulating cancer cells that do not express either EpCAM or Vimentin, and specifically, it was confirmed that expression was confirmed at a rate of approximately 46% in primary HCC and approximately 72% in secondary HCC.
[0098] Therefore, it can be seen that the 63-D7 antibody is a new marker that can detect both intermediate phenotype and EMT phenotype circulating cancer cells that could not be identified by existing EpCAM marker-based circulating cancer cell diagnosis technology.
[0099] PTGFRN (Prostaglandin F2 Receptor Negative Regulator, EWI-F, CD9P-1, CD315) is a type I transmembrane protein of the immunoglobulin superfamily, which negatively affects the prostaglandin F2 receptor. In the present specification, PTGFRN includes a full-length sequence, a fragment that performs an equivalent function, or a polypeptide having a continuous amino acid sequence of PTGFRN (e.g., the PTGFRN amino acid sequence disclosed in FIG. 3c).
[0100] PTGFRN may be, but is not limited to, a PTGFRN derived from a vertebrate, more specifically, a human or mouse.
[0101] The present invention provides an anti-PTGFRN monoclonal antibody, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1.
[0102] The antibody may comprise a single chain variable region (scFv) comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, 99% or more identical to the heavy chain variable region amino acid sequence (SEQ ID NO: 1) produced by the anti-PTGFRN monoclonal antibody clone 63-D7 of the present invention.
[0103] The present invention provides an anti-PTGFRN monoclonal antibody, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2.
[0104] The anti-PTGFRN monoclonal antibody of the present invention may be an antibody comprising a single chain variable region (scFv) comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, 99% or more identical to the light chain variable region amino acid sequence (SEQ ID NO: 2) produced by clone 63-D7.
[0105] The present invention provides an antibody-drug conjugate (ADC) in which a drug is conjugated to the PTGFRN monoclonal antibody of the present invention.
[0106] The monoclonal antibody of the present invention can promote cellular internalization of PTGFRN in various cancer cells, and is therefore suitable as an antibody used in antibody-drug conjugates.
[0107] In antibody-drug conjugates, the drug can be selected by those skilled in the art without limitation on type, depending on the intended purpose. For example, it can be a known anticancer drug, but is not limited thereto. Furthermore, the conjugation method can be selected without limitation using any method known in the art, as long as it allows contact between the antibody and the drug.
[0108] The present invention provides a pharmaceutical composition for treating or preventing cancer comprising the anti-PTGFRN monoclonal antibody of the present invention.
[0109] The present invention provides a method for treating, preventing or diagnosing cancer comprising the anti-PTGFRN monoclonal antibody of the present invention.
[0110] In this specification, cancer may be any one selected from the group consisting of brain and spinal tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophageal cancer, stomach cancer, colon cancer, liver cancer, thyroid cancer, pancreatic cancer, biliary tract cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, germ cell tumor, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma, neuroblastoma, glioblastoma, and skin cancer, but is not limited thereto.
[0111] Metastatic cancer is cancer that has spread from one organ to other organs, including the lymph nodes. The cancer present in the organ where the cancer developed is called the primary cancer. Depending on the tissue to which it spreads, metastases can be brain, bone, liver, or lung metastases. Metastatic cancer can be a malignant tumor. Malignant tumors can include brain and spinal tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophageal cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, biliary tract cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, germ cell tumor, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma, skin cancer, or a combination of these.
[0112] The monoclonal antibody of the present invention is an agonistic antibody against the cancer, capable of stimulating PTGFRN on the surface of cancer cells to promote cancer cell migration and invasiveness. Furthermore, the monoclonal antibody can promote cancer cell migration in primary cancers, thereby preventing the development of early-stage primary cancers or inhibiting their growth.
[0113] The present invention provides a hybridoma producing the above anti-PTGFRN monoclonal antibody.
[0114] In this specification, a hybridoma may include a hybridoma cell or a hybridoma cell line. The hybridoma is a cell created by artificially fusing two different types of cells. It refers to a cell or cell line in which two or more homologous or heterologous cells are fused using a substance that induces cell fusion, such as polyethylene glycol (PEG), or a virus of some type, thereby integrating the different functions of each cell into a single cell. A hybridoma that secretes a monoclonal antibody can be cultured in large quantities in vitro or in vivo.
[0115] The present invention provides a composition for detecting PTGFRN comprising the anti-PTGFRN monoclonal antibody of the present invention.
[0116] The above antigen-antibody complex can be detected using a detection label. For example, the detection label can be selected from enzymes, fluorescent substances, ligands, luminescent substances, microparticles, redox molecules, or radioisotopes, but is not particularly limited thereto.
[0117] The present invention provides a method for providing information for diagnosing cancer, comprising the step of treating a separated sample with an anti-PTGFRN monoclonal antibody of the present invention.
[0118] In this specification, an individual may be a mammal, including a human.
[0119] As used herein, a biological sample refers to a sample obtained from a living organism. The biological sample may be, for example, blood, plasma, bone marrow fluid, lymph, saliva, tears, urine, mucous membrane fluid, amniotic fluid, or a combination thereof.
[0120] In the present specification, the substance that specifically binds to PTGFRN may be an anti-PTGFRN antibody or an antigen-binding fragment thereof, or an aptamer. An aptamer refers to an oligonucleic acid or peptide that binds to a target molecule.
[0121] The present invention provides a method for providing information necessary for determining the level of blood cancer cells, comprising the step of treating a sample isolated from an individual with the anti-PTGFRN monoclonal antibody of the present invention.
[0122] For example, it can provide information necessary for diagnosing metastatic cancer, including the steps of: contacting a biological sample isolated from an individual with the anti-PTGFRN monoclonal antibody of the present invention to bind blood cancer cells in the sample to the anti-PTGFRN monoclonal antibody of the present invention; detecting the blood cancer cells from the reaction mixture; and determining, if the blood cancer cells are detected, that the individual has or is likely to have metastatic cancer.
[0123] Since the anti-PTGFRN monoclonal antibody of the present invention can specifically bind to PTGFRN, PTGFRN can be detected, and furthermore, PTGFRN can be isolated or purified using the composition. The PTGFRN protein can be isolated, identified, or detected by contacting the anti-PTGFRN monoclonal antibody of the present invention with a sample and detecting the formation of an antigen-antibody complex.
[0124] An antigen-antibody complex refers to a combination of PTGFRN and a monoclonal antibody that recognizes it, for the purpose of confirming the presence or absence of PTGFRN in a sample. The antigen-antibody complex can be detected using a detection label. For example, the detection label can be selected from enzymes, fluorescent substances, ligands, luminescent substances, microparticles, redox molecules, or radioisotopes, but is not particularly limited thereto.
[0125] The formation of antigen-antibody complexes can be detected using a colorimetric method, an electrochemical method, a fluorimetric method, a luminometry method, a particle counting method, a visual assessment, or a scintillation counting method. For example, it can be detected by flow cytometry, immunocytochemistry, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), Western blotting, immunoprecipitation assay, immunodiffusion assay, complement fixation assay, protein chip, etc. More specifically, it can be detected through immune precipitation and immunoblotting, which are useful for recovering small amounts of target proteins.
[0126] Specifically, antigen-antibody complexes can be detected using an enzyme-linked immunosorbent assay (ELISA). The ELISA includes various ELISA methods, such as a direct ELISA using a labeled antibody that recognizes an antigen attached to a solid support, an indirect ELISA using a labeled antibody that recognizes a capture antibody in a complex of antibodies that recognize the antigen attached to the solid support, a direct sandwich ELISA using another labeled antibody that recognizes an antigen in a complex of antibodies and antigens attached to the solid support, and an indirect sandwich ELISA using a labeled secondary antibody that recognizes the antibody after reacting it with another antibody that recognizes the antigen in a complex of antibodies and antigens attached to the solid support.
[0127] Circulating tumor cells (CTCs) are rare tumor cells that circulate in the bloodstream after undergoing tumor invasion. Circulating tumor cells are known to be involved in cancer metastasis and recurrence. Circulating tumor cells may be circulating tumor cells that have undergone epithelial-mesenchymal transition.
[0128] Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells lose cell polarity and intercellular adhesion and transform into mesenchymal cells, becoming migratory and invasive. This transition is essential for many developmental processes, including mesoderm formation and neural tube formation, and is known to be involved in wound healing, organ fibrosis, and the initiation of metastasis during cancer progression.
[0129] The circulating cancer cells may be circulating cancer cells that have undergone epithelial-mesenchymal transition, circulating cancer cells that have not undergone epithelial-mesenchymal transition, or circulating cancer cells that are undergoing epithelial-mesenchymal transition, and preferably, but not limited to, circulating cancer cells that have undergone epithelial-mesenchymal transition or are undergoing epithelial-mesenchymal transition.
[0130] Cancer cells in the blood may be neither epithelial nor mesenchymal cells.
[0131] In the present disclosure, detection of circulating cancer cells involves isolating a complex comprising circulating cancer cells and a substance that specifically binds to PTGFRN from a biological sample. Detection methods include electron microscopy, microfiltration, centrifugation, microfluidics, immunostaining, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), flow cytometry, fluorescein activated cell sorting (FACS), or a combination thereof. In addition, the detection method may be polymerase chain reaction (PCR), electrophoresis, Northern blotting, Western blotting, or a combination thereof.
[0132] In addition, according to one specific example of the present invention, PTGFRN was confirmed to be expressed in liver cancer, lung cancer, colon cancer, pancreatic cancer, and thyroid cancer cell lines, and 97% of hepatocellular carcinoma patients were detected with circulating cancer cells. At the same time, since it was confirmed to be simultaneously expressed with Vimentin, an EMT marker, in about 53% of primary HCCs and about 28% of secondary HCCs, it was confirmed that it is useful for detecting circulating cancer cells showing an EMT phenotype and can be used for diagnosing metastatic cancer. In addition, circulating cancer cells recognized by 63-D7 were simultaneously expressed in about 46% of primary HCCs and about 72% of secondary HCCs, even in intermediate circulating cancer cells that do not express either EpCAM or Vimentin, so it can be useful for detecting circulating cancer cells by complementing the shortcomings of the existing EpCAM marker-based circulating cancer cell diagnosis technology.
[0133] The blood cancer cells may be derived from a primary cancer selected from the group consisting of brain and spinal tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophageal cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, biliary tract cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, germ cell tumor, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma, and skin cancer.
[0134] The present invention provides a method for providing information necessary for determining the level of cancer cells in the blood, further comprising the step of treating a sample isolated from an individual with a substance that specifically binds to EpCAM. The present invention provides a method for providing information necessary for determining the level of cancer cells in the blood, wherein the substance that specifically binds to EpCAM is an anti-EpCAM antibody or an antigen-binding fragment thereof.
[0135] EpCAM is a Ca receptor in epithelial cells. 2+ EpCAM is a transmembrane glycoprotein that mediates intercellular adhesion. EpCAM is known to be involved in cell signaling, migration, proliferation, and differentiation. EpCAM may be human or mouse EpCAM. For example, EpCAM may be a polypeptide having the amino acid sequence of GenBank Accession No. NP_002345. For example, EpCAM may be a polypeptide encoded by the nucleotide sequence of GenBank Accession No. NM_002354. The substance that specifically binds to EpCAM may be an anti-EpCAM antibody or an antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof is as described above.
[0136] In the method for providing information necessary for determining the level of blood cancer cells of the present invention, the blood cancer cells may be blood cancer cells undergoing epithelial-mesenchymal transition or undergoing epithelial-mesenchymal transition.
[0137] In the method for providing information necessary for determining the level of blood cancer cells of the present invention, the blood cancer cells may be in a hybrid E / M state.
[0138] In the method for providing information necessary for determining the level of blood cancer cells of the present invention, the blood cancer cells may be neither epithelial cells nor mesenchymal cells.
[0139] In the method for providing information necessary for determining the level of blood cancer cells of the present invention, the blood cancer cells may be blood cancer cells in the blood of a patient with liver cancer, lung cancer, colon cancer, thyroid cancer, pancreatic cancer, malignant melanoma, breast cancer, neuroblastoma, or glioblastoma.
[0140] In the method for providing information necessary for determining the level of blood cancer cells of the present invention, blood cancer cells may further express B7-H3 (CD276) protein.
[0141] The present invention provides a method for providing information necessary for predicting the prognosis of cancer metastasis, comprising the step of detecting PTGFRN by treating a sample isolated from an individual with the anti-PTGFRN monoclonal antibody of the present invention.
[0142] The present invention provides a method for providing information necessary for predicting the prognosis of cancer metastasis, further comprising a step of providing information that if the level of detected PTGFRN is higher than that of the control group, the prognosis of cancer metastasis is worse than that of the control group.
[0143] The present invention provides a method for screening the efficacy of an anticancer drug, comprising the step of detecting PTGFRN by treating a sample isolated from a patient administered an anticancer drug with the anti-PTGFRN monoclonal antibody of the present invention.
[0144] The present invention provides a method for screening the efficacy of an anticancer drug, further comprising a step of predicting that the anticancer drug has a better anticancer metastasis inhibition efficacy than the control group if the level of detected PTGFRN is lower than that of the control group.
[0145] The present invention provides a composition for detecting blood cancer cells, which comprises a substance that binds to PTGFRN.
[0146] The present invention provides a composition for separating, purifying, detecting and detecting the concentration of PTGFRN protein, which comprises a substance that binds to PTGFRN.
[0147] The composition for detecting blood cancer cells of the present invention may further include a substance that specifically binds to an epithelial cell adhesion molecule (EpCAM).
[0148] In the composition for detecting blood cancer cells of the present invention, the substance binding to PTGFRN may be an anti-PTGFRN antibody or an aptamer. The anti-PTGFRN antibody may be a monoclonal antibody or a polyclonal antibody.
[0149] Circulating cancer cells may be, but are not limited to, circulating cancer cells in the blood of patients with liver cancer, lung cancer, colon cancer, thyroid cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma, or glioblastoma. Circulating cancer cells may have undergone epithelial-mesenchymal transition (EST) or are undergoing epithelial-mesenchymal transition (EST). Circulating cancer cells may be in a hybrid E / M state.
[0150] In the composition for detecting blood cancer cells of the present invention, the substance binding to PTGFRN may be an anti-PTGFRN antibody of the present invention.
[0151] The composition for detecting blood cancer cells of the present invention may be included in a kit form. For example, when the kit of the present invention is applied to immunoassays, the kit of the present invention may optionally include a secondary antibody and a labeling substrate. Furthermore, the kit of the present invention may be manufactured into multiple separate packaging or compartments containing the aforementioned reagent components.
[0152] The composition for detecting blood cancer cells of the present invention may be included in the form of a microarray. In the microarray, the monoclonal antibody is used as a hybridizable array element and is immobilized on a substrate. Preferred substrates include suitable rigid or semi-rigid supports, such as membranes, filters, chips, slides, wafers, fibers, magnetic or non-magnetic beads, gels, tubing, plates, polymers, microparticles, and capillaries. The hybridizable array elements are arranged and immobilized on the substrate, and such immobilization can be performed by chemical bonding or covalent bonding methods such as UV irradiation. For example, the hybridizable array elements can be bound to a glass surface modified to include an epoxy compound or an aldehyde group, and can also be bound to a polylysine-coated surface by UV irradiation. Furthermore, the hybridizable array elements can be bound to the substrate via a linker (e.g., ethylene glycol oligomers and diamines).
[0153] The present invention provides a composition for monitoring cancer metastasis, comprising a substance that binds to PTGFRN. The substance is not limited as long as it can measure the level of PTGFRN.
[0154]
[0155] Example 1. Cancer cell line culture and research ethics
[0156] 1-1. Cancer cell line culture
[0157] Human embryonic stem cells H9 were purchased from the Wicell Research Institute and cultured according to the provided protocol. The culture medium contained DMEM / F12 (Invitrogen, Seoul, Korea), 20% Knockout SR (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma, St Luis, MO, USA), 2 mM glutamine (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 100 U / mL penicillin G (Sigma), 100 μg / mL streptomycin (Sigma), and 4 ng / mL bFGF (PeproTech, Rocky Hill, NJ). Human embryonic carcinoma NT-2 / D1 cells were purchased from ATCC (Manassas, VA, USA) and cultured according to the provided protocol. Human hepatocellular carcinoma (Huh7, HepG2, SNU387, SNU449), non-small cell lung cancer (A549, NCI-H358, NCI-H460, NCI-H1703, NCI-H23), and thyroid cancer (SNU-790) cells were purchased from the Korea Cell Line Bank (KCLB, Seoul, Korea). Human normal lung fetal fibroblasts (MRC5), colon cancer (Colo205), and pancreatic cancer (BxPC3) cells were purchased from ATCC, and human hepatocytes were purchased from Termo Fisher Scientific (Waltham, USA) and cultured according to the provided protocol.
[0158]
[0159] 1-2. Research ethics and patient consent
[0160] Human peripheral blood mononuclear cells (PBMCs) were isolated from donors by Ficoll-Paque gradient centrifugation using the method provided by the Ficoll-Paque Plus method (GE Healthcare, Seoul, Korea). Blood samples from liver cancer patients undergoing liver resection at the Department of Surgery, Samsung Medical Center, Seoul were collected into heparin-coated tubes after obtaining informed consent. All procedures were approved by the Seoul Samsung Hospital Institutional Review Board (IRB) and were transferred to Sejong University in good faith for analysis. Cancer staging was analyzed using the criteria specified by the American Joint Committee on Cancer (AJCC, 2010).
[0161]
[0162] Example 2. Selection of 63-D7 antibody
[0163] Among the 70 antibodies specific for human embryonic stem cells developed in a previous study (Choi HS, et al., Cell Tissue Res. vol. 333, pp. 197-206, 2008), flow cytometry was performed to observe the degree of binding to two types of liver cancer cells (Huh7, HepG2) and two types of lung cancer cells (A549, NCI-H358). Specifically, Huh7, HepG2, A549, and NCI-H358 cancer cells were treated with 0.05% trypsin to detach the cells, washed with PBS (pH 7.4), and then filtered using a 40 μm strainer (BD Biosciences) to separate them into single cells. Human embryonic stem cells (H9) and human peripheral blood mononuclear cells (PBMC) were also used in the analysis. 5×10 cells 5After mixing the cells with PBA (1% bovine serum albumin, 0.02% NaN3 in PBS, pH 7.4), the antibodies were reacted for 30 minutes at 4 °C. After washing twice with PBA, the primary antibody and the corresponding anti-mouse IgG-FITC (BD Biosciences) were reacted for another 30 minutes at 4 °C. After washing twice with PBA, the antibody reactivity was analyzed for propidium iodide (PI)-negative cells using FACS Calibur and Cell Quest software (BD sciences). As a result, 63-D7, 246-D7, and 247-B9 antibodies that bound to human embryonic stem cells (H9), liver cancer cell lines (Huh7, HepG2), and lung cancer cell lines (A549) but not to PBMCs were selected (Fig. 1a, Fig. 1b). Among these, 246-D7 and 247-B9 bound to the epithelial lung cancer cell line NCI-H358, but 63-D7 did not bind. To analyze the characteristics of the antibodies, 63-D7, 246-D7, and 247-B9 antibodies were purified by protein G-agarose column chromatography, and the purified antibodies were biotinylated according to the protocol provided using the DSB-XTM Biotin Protein Labeling Kit (Molecular Probes, Seoul, Korea).
[0164] To investigate whether the three antibodies could detect circulating cancer cells in the blood of patients with liver cancer, PBMCs were isolated from the blood of one healthy adult and eight patients with hepatocellular carcinoma (HCC) using the same method as in Example 1-2. The recovered PBMC cells were divided into 2 to 4 cells and attached to poly-L-lysine-coated slides according to the number of cells. The prepared slides were treated with 4% paraformaldehyde (PFA) for 10 minutes at room temperature to fix the cells. All PBS used in cell staining always contained 1 mM CaCl to prevent cell loss. 2+ , 0.5mM Mg 2+PBS (pH 7.4) containing 10% horse serum, 0.1% BSA, PBS, pH 7.4 was used. After washing with PBS, the cells were blocked for 1 hour with blocking solution (10% horse serum, 0.1% BSA, PBS, pH 7.4). Then, they were reacted with mouse antibody CD45 antibody (BD Biosciences, Seoul Korea) at room temperature, protected from light, for 1 hour, followed by reaction with anti-mouse IgG-Alexa488 (Invitrogen, 1:3000) for another 1 hour at room temperature, protected from light. After washing with PBS (pH 7.4), 5 μg of 63-D7-biotin, 246-D7-biotin, and 247-B9-biotin antibodies were added to stain the antigens recognized by each antibody, and the cells were reacted for 12 hours at room temperature, protected from light, for 1 hour. After washing with PBS, the cells were reacted with Cy3-conjugated streptavidin (Vector Laboratories, BURLINGAME, CA, USA, 1:3000) for 1 hour at room temperature, protected from light. After washing with PBS, the nuclei were stained with DAPI (4,6-diamidino-2-phenylindole). When counting circulating cancer cells positive for antibodies in cells collected from the blood, only DAPI-positive cells were counted to eliminate nonspecific binding caused by blood. As a result, antibody-positive cells were detected in the blood of most liver cancer patients, although they were not detected in the blood of normal people. In particular, the 63-D7 antibody was selected as an antibody requiring further analysis because it could detect a total of 51 circulating cancer cells in 6 out of 8 patients (Fig. 1c, Fig. 1d).
[0165]
[0166] Example 3. Analysis of 63-D7 binding to various cells using flow cytometry.
[0167] To determine whether monoclonal antibody 63-D7 binds to various cancer cells and normal cells in addition to embryonic stem cells (H9), liver cancer (Huh7, HepG2), and lung cancer (A549, NCI-H358), various cancer cells (SK-Hep1, 8505C, A375, MCF-7, MDA-MB-435, SH-SY5Y, U87-MG) including embryonic cancer (NT2 / D1), metastatic liver cancer (SNU387, SNU449), lung cancer (NCI-H460, NCI-H1703, NCI-H23), colon cancer (Colo205, HCT116), thyroid cancer (SNU790), and pancreatic cancer (BxPC3), as well as human embryonic kidney cells (HEK293FT), bone marrow-derived mesenchymal stem cells (BM-MSC), human dermal fibroblasts (HDF), and human peripheral blood cells (PC1). Flow cytometry was performed using primary blood mononuclear cells (PBMCs), normal lung fetal fibroblasts (MRC5), dental pulp cells (DPCs), and normal hepatocytes. Specifically, cells were detached by treating with 0.05% trypsin, washed with phosphate-buffered saline (PBS) (pH 7.4), and filtered using a 40 μm strainer (BD Biosciences) to separate them into single cells. 5 × 10 cells 5Cells were mixed with PBA (1% bovine serum albumin, 0.02% NaN3 in PBS, pH 7.4) and reacted with 63-D7 antibody at 4°C for 30 minutes. After washing twice with PBA, the cells were further reacted with anti-mouse IgG-FITC (BD Biosciences) corresponding to the primary antibody at 4°C for 30 minutes. After washing twice with PBA, antibody reactivity was analyzed for propidium iodide (PI)-negative cells using FACS Calibur and Cell Quest software (BD sciences). As shown in Figure 2, 63-D7 antibody binds to all cancer cells, including hepatoma cells, but does not bind to H358 epithelial lung cancer cells. Furthermore, it does not bind to normal cells such as PBMC, dental pulp cells (DPC), and MRC5, nor does it bind to normal hepatocytes, demonstrating cancer cell-specific binding (Fig. 2). The experimental results are shown in Fig. 2 and Table 1 below.
[0168] Cell lines63-D7H9Human embryonic stem cell++NT2 / D1Human embryonal carcinoma+HepG2Human hepatocellular carcinoma++Huh7Human hepatocellular carcinoma+++SNU-387Human hepatocellular carcinoma++SNU-449Human hepatocellular carcinoma++SK-Hep-1Human hepatic adenocarcinoma+A549Human non-small cell lung adenocarcinoma++NCI-H358Human non-small cell lung adenocarcinoma-NCI-H460Human non-small cell lung adenocarcinoma++NCI-H1703Human non-small cell lung adenocarcinoma+NCI-H23Human non-small cell lung adenocarcinoma+Colo205Human colorectal adenocarcinoma+++HCT116Human colorectal carcinoma+++SNU-790Human thyroid carcinoma++8805CHuman thyroid carcinoma++BxPC-3Human pancreatic carcinoma+++A375Human melanoma+++MCF-7Human breast adenocarcinoma++MDA-MB-435Human breast metastatic carcinoma+++SH-SY-5YHuman neuroblastoma,Bone+U87-MGHuman glioblastoma+++HEK293FTHuman embryonic kidney cell+++BM-MSCHuman bone marrow-mesenchymal stem cell+HDFHuman dermal fibroblast cell+PBMCHuman peripheral blood mononuclear cells-MRC5Human normal lung fibroblast-DPCHuman dental pulp cells-HepatocyteHuman normal hepatocyte-,
[0169]
[0170] Example 4. Isolation of antigen bound by antibody 63-D7
[0171] To analyze the cell surface antigen recognized by the 63-D7 antibody, an immunoprecipitation method was performed, in which only cell surface proteins were labeled with biotin and then precipitated with 63-D7 to isolate them. NT-2 / D1 cancer cells that bind well were washed twice with PBS (pH 7.4), and then a solution of NHS-Sulfo-LC-biotin (Pierce) dissolved in PBS (pH 8.0) was added, reacted at 4°C for 30 minutes, and then washed twice with PBS (pH 8.0). Afterwards, the reaction was carried out at 4 °C for 30 min using lysis buffer (25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 2 μg / ml aprotinin, 100 μg / ml PMSF, 5 μg / ml leupeptin, 1 mM NaF, 1 mM Na3VO4), and the nuclei were removed by centrifugation at 12,000 rpm for 40 min and stored at -70 °C until use to prepare a protein solution. After adding protein-G-plus agarose (Merck millipore, Darmstadt, Germany) to the prepared protein solution, approximately 1 × 10 720 μl of protein-G-agarose was added to the cell extract of the cell and reacted at 4 °C for 2 hours. After centrifugation, molecules binding to protein-G-plus agarose were removed, and the remaining supernatant was collected and used to immunoprecipitate molecules binding to 63-D7. To immunoprecipitate the surface antigen recognized by 63-D7, 5 μg of antibody was added to the collected supernatant and reacted at 4 °C for 12 hours, and then 20 μl of protein-G-plus agarose was added and reacted for another 3 hours at 4 °C. The immunoprecipitated immune mixture was washed five times using a dissolution solution. After that, 5× sample buffer was added to elute the antigen bound to the antibody, and the mixture was boiled at 100 °C for 10 minutes, developed using 10% SDS-PAGE, and Western blotting was performed on a nitrocellulose membrane. After blocking the membrane with 5% skim milk powder for 2 hours at room temperature, the membrane was washed three times with PBST [phosphate buffered saline (PBS) containing 0.05% Tween 20, pH 7.4], and the Western membrane was reacted with streptavidin-HRP (Streptavidin-HRP, GE healthcare) at room temperature for 1 hour to allow binding to the biotin-labeled surface antigen immunoprecipitated by 63-D7. After washing with PBST, the bound protein was confirmed using an ECL detection kit (GE healthcare). As shown in Fig. 3a, it was found that the 63-D7 antibody in NT-2 / D1 cells recognized and immunoprecipitated the surface antigen labeled with biotin with a size of approximately 130 kDa (Fig. 3a).
[0172]
[0173] Example 5. Identification and verification of antigen immunoprecipitated by antibody 63-D7.
[0174] 5-1. Identification of antigen immunoprecipitated by antibody 63-D7
[0175] To identify the antigen recognized by 63-D7, a polyacrylamide gel containing proteins immunoprecipitated by 63-D7 was stained with PageBlue Protein Staining Solution (Thermo Fischer Scientific) according to the supplier's protocol (Fig. 3b). The protein band stained at 130 kDa, presumed to be a protein immunoprecipitated by 63-D7, was excised from the gel and subjected to liquid chromatography with tandem mass spectrometry (LC-MS / MS) analysis (ProteomeTech, Seoul, Korea). The ProFound search engine developed by Rockefeller University (http: / / 129.85.19.192 / profound_bin / WebProFound.exe) was used to identify proteins from the analyzed mass spectra. As a result, the antigen protein recognized by 63-D7 was confirmed to be Homo sapiens Prostaglandin F2 receptor negative regulator (PTGFRN) (Fig. 3c). The underlined amino acids in Figure 3c represent the peptides actually identified by mass spectrometry, showing that 71 amino acids are identical to PTGFRN.
[0176]
[0177] 5-2. Verification of antigen immunoprecipitated by antibody 63-D7
[0178] To confirm that the antigen protein of monoclonal antibody 63-D7 is PTGFRN, immunoprecipitation, Western blotting, gene knockdown by RNA interference, and flow cytometry were performed using commercially available antibodies, gene expression vectors, siRNA, and shRNA against PTGFRN.
[0179] To confirm that the protein immunoprecipitated by monoclonal antibody 63-D7 was PTGFRN, a mouse anti-PTGFRN monoclonal antibody (α-PTGFRN, R&D system) was purchased and used for immunoprecipitation and Western blotting. A cell lysate (150 μg) was prepared from A549 cells labeled with biotin as described in Example 4, and the lysate was immunoprecipitated with monoclonal antibody 63-D7 (5 μg) and α-PTGFRN (2.5 μg) as described above. Thereafter, the eluted protein and the negative control protein without antibody (No Ab) were separated through 10% SDS-PAGE, transferred to a nitrocellulose membrane, and Western blotting was performed with a known mouse α-PTGFRN antibody. As a result, approximately 130 kDa PTGFRN immunoprecipitated from 63-D7 and α-PTGFRN was simultaneously detected, confirming that they could recognize and immunoprecipitate PTGFRN (Fig. 4a). The membrane was incubated with Stripping solution (100 mM 2ME, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) at 50 °C for 30 min with gentle shaking, washed twice with PBST for 10 min each, and blocked with 5% skim milk powder for 1 h at room temperature. After washing three times with 0.1% PBST, streptavidin-HRP (SA-HRP, 1:5000) was added and reacted at room temperature for 1 h. Then, the membrane was washed three times with PBST, and the biotin-labeled protein was confirmed using an ECL detection kit. As a result, PTGFRN with a size of approximately 130 kDa, identical to cell surface PTGFRN, was detected in the immunoprecipitate of 63-D7 and α-PTGFRN (Fig. 4b). These results demonstrate that 63-D7 binds to cell surface PTGFRN.
[0180] An experiment was performed to distinguish whether antibody 63-D7 directly recognizes and immunoprecipitates PTGFRN or indirectly recognizes and precipitates it. PTGFRN gene expression vector pcDNA3.1(+)-PTGFRN-DYK (GeneScript, Piscataway, NJ, USA) was purchased, and FLAG-tagged recombinant PTGFRN was overexpressed in human embryonic kidney cells HEK293FT. The cell lysates were immunoprecipitated and Western blotting was performed using mouse anti-FLAG monoclonal antibody (α-FLAG) (Invitrogen), mouse anti-PTGFRN monoclonal antibody (α-PTGFRN) (AbCAM), and 63-D7. To overexpress PTGFRN in human embryonic kidney cells HEK293FT, 2.5 × 10 cells per well were seeded in a 6-well cell culture plate. 5HEK293FT cells were cultured for 24 hours, and 2 μg of the pcDNA3.1(+)-PTGFRN-DYK vector DNA was mixed with 6 μg of polyetherimide (PEI) (DNA: PEI = 1:3), and the mixture was reacted at room temperature for 20 minutes. Transfection was performed by adding the mixture to the cell culture medium. After further culture for 72 hours, a cell lysate was prepared from the cells using a cell lysis buffer as described in Example 4. The cell lysate was immunoprecipitated with 63-D7, anti-FLAG antibody, and α-PTGFRN as described above, and the eluted protein and the negative control protein without antibody (No Ab) were separated using 10% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk powder at room temperature for 1 hour. After washing three times with 0.1% TBST, the well-known mouse anti-FLAG antibody, or α-PTGFRN, 63-D7 were reacted at 4°C for 16 hours. After washing three times with 0.1% TBST, the anti-mouse IgG-HRP (1:10,000; Millipore) was reacted for another 1 hour at room temperature. After washing three times with 0.1% TBST, the cells were confirmed using an ECL detection kit (Fig. 4c). As a result, it was observed that all proteins immunoprecipitated by anti-FLAG, α-PTGFRN, and 63-D7 were recognized by anti-FLAG (Fig. 4c top), α-PTGFRN (Fig. 4c middle), and 63-D7 (Fig. 4c bottom). From these results, it was verified that the monoclonal antibody 63-D7 of the present invention is an antibody that directly recognizes the PTGFRN protein present on the surface of the human embryonic cancer cell line NT-2 / D1.
[0181]
[0182] Example 6. Functional analysis of PTGFRN in liver cancer cells
[0183] 6-1. Knockdown using siRNA in liver cancer cell lines
[0184] To investigate how PTGFRN, the antigen of antibody 63-D7, affects the growth of hepatoma cells, two types of siRNA targeting PTGFRN (Bioneer, Daejeon, Korea) were purchased and transiently knocked down in hepatoma cell lines Huh7 and SNU449. 8.0 x 10 5 After dividing the cells into cells / well, the next day, 100 nM of negative control siRNA (siCon) (Genolution, Seoul, Korea), two types of siRNA against PTGFRN (siPTGFRN#1, siPTGFRN#2) (Table 2), and Lipofectamine RNAiMAX (Invitrogen) were diluted in TOM (Welgene, Gyeongsan, Korea) and incubated at room temperature for 5 min. Afterwards, each siRNA dilution and RNAiMAX dilution were mixed and incubated at room temperature for 20 min. The siRNA-lipofectamine mixture was added to each cell after replacing the medium and incubated for 24 h. After 24 h, the medium was replaced with fresh culture medium and incubated for an additional 48 h. At 72 hours after transfection, cells were detached with 0.05% trypsin-EDTA (Welgene, Gyeongsan, Korea), neutralized with culture medium containing 10% fetal bovine serum (Corning), and washed twice with PBS (pH 7.4). 3.0 x 10 5RNA was isolated from dog cells using RNAiso (Takara) according to the manufacturer's instructions. cDNA was synthesized using PrimeScript (Takara) according to the manufacturer's instructions. Subsequently, qPCR was performed using primers targeting PTGFRN and GAPDH, and Power SYBR Green PCR Master Mix (applied biosystems), with GAPDH used as the reference gene. The specific sequences of the primers used are shown in Table 2.
[0185] NameSequenceReference / SupplierPrimers for human PTGFRNForward: 5'-ACAACAGCTGGGTGAAAAGC-3' (SEQ ID NO: 9)Reverse: 5'-TTTCATTGGGACTGGAGAGG-3' (SEQ ID NO: 10)Primers for human GAPDHForward: 5'-ACAGCGACACCCACTCCTCC-3' (SEQ ID NO: 11)Reverse: 5'-GAGGTCCACCACCCTGTTGC-3' (SEQ ID NO: 12)siControl5'-UUCUCCGAACGUGUCACGUtt-3' (SEQ ID NO: 13)siPTGFRN#15'-CUCCUACAUUUACUGGUUtt-3' (SEQ ID NO: 14)Bioneer #5738siPTGFRN#25'-GUCCCAAUGAAACGAAGUAtt-3' (SEQ ID NO: 15)Bionics #2079shScrambleTet-pLKO-puro-ScrambledAddgene #47541shPTGFRN#15'-ctagcGCCTTTGATGTGTCCTGGTTTtactagtAAACCAGGACACATCAAAGGCTTTTTg-3'(SEQ ID NO: 16)TRCN00000574485'-aattcAAAAAGCCTTTGATGTGTCCTGGTTTactagtaAAACCAGGACACATCAAAGGCg-3'(SEQ ID NO: 17)shPTGFRN#25'-ctagcCCTATTGAGATAGACTTCCAAtactagtTTGGAAGTCTATCTCAATAGGTTTTTg-3'(SEQ ID NO: 18)TRCN00000574525'-aattcAAAAACCTATTGAGATAGACTTCCAAactagtaTTGGAAGTCTATCTCAATAGGg-3'(SEQ ID NO: 19)
[0186]
[0187] As a result, the knocked-down cancer cells showed a reduction efficiency of PTGFRN mRNA of 85-88% and 71-72% in Huh7 and SNU449, respectively, compared to the negative control group (Fig. 5a). In addition, when flow cytometry analysis was performed using cells with PTGFRN knocked-down as in Example 3, it was observed that the binding of the 63-D7 antibody was reduced by 51-75% and 71-78% in Huh7 and SNU449, respectively, in the cells with PTGFRN knocked-down, indicating that PTGFRN expression was successfully knocked-down (Figs. 5b and 5c).
[0188]
[0189] 6-2. Clonogenic survival analysis of PTGFRN knockdown liver cancer cells using siRNA and shRNA.
[0190] Next, to investigate the role of PTGFRN in the survival and proliferation of hepatoma cells, a clonogenic survival assay was performed using the PTGFRN knockdown Huh7 cells and SNU449 cells prepared in the above experiment. The PTGFRN knockdown Huh7 cells prepared in the above experiment were detached with 0.05% Trypsin-EDTA (Welgene, Gyeongsan, Korea) and neutralized with cell culture medium containing 10% fetal bovine serum (Corning). The cells were passed through a 40 μm strainer (SPL, Pocheon, Korea) to prepare single cells. 2.0 × 10 per well in a 6-well plate. 3The cells were spread out one by one and allowed to adhere as single cells, and cultured for 14 days at 37°C and 5% CO2. The formed colonies were stained with 0.5% (w / v) crystal violet solution, and the total number of colonies was analyzed. The clonogenic survival assay in PTGFRN knockdown Huh7 cells and SNU449 cells showed a 41-43% and 29-35% decrease, respectively (Fig. 5d, Fig. 5e). These results demonstrate that PTGFRN is an important cell surface molecule that enhances liver cancer cell survival and promotes proliferation under low-density stress.
[0191] To analyze how PTGFRN, the antigen of antibody 63-D7, affects the long-term clonogenic survival of hepatocellular carcinoma cells, we performed sustained gene knockdown in hepatocellular carcinoma cell lines using shRNA targeting the PTGFRN gene. The negative target scramble and shRNA sequences #1 and #2 (TRCN0000057448, TRCN00000057452) targeting PTGFRN were inserted into the EZ-tet-PLKO vector (Addgene, 85996) and transfected with psPAX2 and pMD2G into human embryonic kidney cells HEK293FT cells (Table 2). Approximately 48 and 72 hours after transfection, the cell culture medium was harvested and used to infect hepatocellular carcinoma cell lines Huh7 and SNU449. Cells with the target gene inserted were selected for one week in RPMI-1640 medium containing 10% fetal bovine serum (Corning) and 2 μg / ml puromycin (Gibco). After selection, the cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Corning) and 100 ng / ml doxycycline (Sigma) to induce knockdown, and then cultured for 72 hours. The cultured cells were detached with 0.05% trypsin-EDTA (Welgene), neutralized with cell culture medium containing 10% fetal bovine serum (Corning), and then harvested. PTGFRN protein expression in the harvested cells was analyzed by Western blot, and PTGFRN expression was observed to be reduced by 57-84% and 88-89% in Huh7 and SNU449, respectively (Fig. 6a). When the binding of 63-D7 was analyzed using the flow cytometry method of Example 3, it was confirmed that the cell surface PTGFRN expression was knocked down well by two types of shPTGFRN (shPTGFRN#1, shPTGFRN#2) in both Huh7 and SNU449 liver cancer cells by 44-49% and 52-61%, respectively (Fig. 6b, Fig. 6c).Among these, clonogenic survival assays were performed using SNU449 cells in the same manner as described above, and as a result, a 90% reduction was observed with shPTGFRN#1 (Figs. 6d, 6e) and a 47% reduction was observed with shPTGFRN#2 (Figs. 6f, 6g). These results demonstrate that PTGFRN is an important cell surface molecule that continuously provides cancer stemness in liver cancer cells, enhances liver cancer cell survival, and promotes proliferation.
[0192]
[0193] 6-3. Analysis of cancer cell migration and invasiveness in PTGFRN knockdown liver cancer cell lines
[0194] Next, to investigate the role of PTGFRN in the migration and metastasis of liver cancer cells, transwell experiments were performed using Huh7 and SNU449 cells in which PTGFRN was knocked down with shPTGFRN#1 and shPTGFRN#2, respectively. The PTGFRN knockdown Huh7 cells prepared through the above experiment were detached with 0.05% Trypsin-EDTA (Welgene), neutralized with cell culture medium containing 10% fetal bovine serum (Corning), and then passed through a 40 μm strainer (SPL) to prepare single cells.
[0195] To assess cell motility, 3.0 x 10 4After diluting the cells in RPMI1640 medium, they were placed in a transwell chamber, and RPMI-1640 medium containing 10% Fetal Bovine Serum (Corning) was used as a chemoattractant to induce migration. After culturing for 37 hours in a 37 ℃ incubator supplied with 5% CO2 and 95% air, they were washed twice with PBS (pH 7.4), and non-migrated cells were removed with a cotton swab and fixed with 4% PFA. The fixed cells were stained with 0.5% crystal violet solution, repeated three times, and statistically represented. As a result, migration was reduced by 72% in PTGFRN knockdown Huh7 cells and 74-85% in SNU449 cells (Fig. 7a, Fig. 7b).
[0196] To investigate the invasiveness of liver cancer cells for metastasis, 0.1 ml of RPMI-1640 solution containing 250 μg / ml Matrigel was coated on transwells at 37°C for 2 hours, and the same experiment as above was performed. Invasiveness was reduced by 82-93% in PTGFRN-knockdown Huh7 cells and by 57-91% in SNU449 cells (Fig. 7c, 7d).
[0197] Thus, PTGFRN deficiency reduced motility and invasiveness in both Huh7 and SNU449 cells, suggesting that PTGFRN is a key cell surface molecule that promotes migration and invasiveness, which are crucial for metastasis in hepatocellular carcinoma cells.
[0198]
[0199] 6-4. Cell proliferation analysis of PTGFRN knockdown liver cancer cells
[0200] To analyze whether PTGFRN-knockdown hepatoma cells Huh7 and SNU449 bind well to various extracellular matrices (ECM), a cell spreading assay was performed. For the cell spreading assay, 200 μg / ml Matrigel, 20 μg / ml Collagen I, 20 μg / ml Collagen IV, and 0.1% Gelatin were coated and cultured for 2 hours in a 37°C incubator supplied with 5% CO2 and 95% air. After that, PTGFRN-knockdown hepatoma cells Huh7 and SNU449 were prepared and 5.0 X 10 4After diluting to a concentration of 10 cells / ml, the cells were dispensed onto plates that had been washed twice with PBS (pH 7.4) and cultured for 20-60 minutes. After fixing with 4% paraformaldehyde for 10 minutes at room temperature, the cells were washed with PBS (pH 7.4), and the cells were photographed under a microscope. The photographs of the cells observed under a microscope were analyzed using the Image J program. In the analysis of Huh7 cells, shScramble had many spread cells that adhered to the bottom, but in the two types of shPTGFRN, many unspread cells were observed because the cells did not adhere well to the bottom and had a round, floating shape (Fig. 8a, Fig. 8b). The same experiment was performed in PTGFRN knockdown SNU449 cells, and the results showed that the binding to the extracellular matrix was reduced (Fig. 8c, Fig. 8d). A statistical analysis of the results of three replicates of the same experiment revealed that in Huh7, regardless of the type of shPTGFRN knockdown, the cell proliferation capacity of hepatoma cells was reduced on Collagen I, Collagen IV, and Gelatin extracellular matrices, except for Matrigel (Fig. 8b). In SNU449, shPTGFRN#2 knockdown showed no difference in cell proliferation capacity on Matrigel, but a decrease in cell proliferation capacity on the remaining three types of extracellular matrices was observed (Fig. 8d). These results demonstrate that PTGFRN is important for the attachment and proliferation of hepatoma cells to most extracellular matrices.
[0201]
[0202] 6-5. Analysis of the immune evasion ability of PTGFRN-knockdown liver cancer cells against NK cells
[0203] Because cancer cells thrive when they evade the cytotoxic effects of immune cells, most advanced cancer cells express immune checkpoint molecules that allow them to evade attack by invading immune cells. To determine whether PTGFRN, expressed in liver cancer cells, serves as an immune checkpoint molecule crucial for immune evasion, we analyzed the cytotoxicity of PTGFRN-knockdown SNU449 cells, generated using shScramble and shPTGFRN#2, when co-cultured with the NK cell line NK92.
[0204] PTGFRN knockdown SNU449 cells prepared through the above experiment were detached with 0.05% Trypsin-EDTA (Welgene, Gyeongsan, Korea), neutralized with cell culture medium containing 10% fetal bovine serum (Corning) and 200 ng / ml doxycycline (Sigma), and seeded at 2.0 X 10 per well in a 12-well plate. 4Cells were seeded one by one and cultured in an incubator at 37°C and 5% CO2 for one day. One day later, effector cells (NK92): target cells (shPTGFRN-SNU449) were mixed at an E:T ratio of 1:1, 2.5:1, and 5:1 in a medium containing 400 U / ml IL2 (Peprotech), 10% fetal bovine serum (Corning), and 200 ng / ml doxycycline (Sigma), seeded, and cultured for 2 days at 37°C and 5% CO2. After culture, floating NK92 cells were washed and removed, and the SNU449 target cells that remained attached to the bottom and survived were stained with a 0.5% (w / v) crystal violet solution. After drying the plate, crystal violet was dissolved in a 50% ethanol, 0.1 M sodium citrate solution, and the absorbance (OD540) was measured at 540 nm. When the relative OD540 was compared, shPTGFRN#2 showed an OD540 that was approximately 50% lower than shScramble due to low clonogenic viability, and when co-cultured with NK92, it showed an OD540 that was additionally approximately 50% lower (Fig. 9a, Fig. 9b). These results demonstrate that NK cell-mediated hepatoma cell killing is further enhanced when PTGFRN is deficient. Next, when the number of NK cells was increased by adjusting the E:T ratio to 1:1, 2.5:1, and 5:1, the degree of hepatoma cell killing was analyzed using the following formula.
[0205] [formula]
[0206] NK cytotoxicity (%) = {1 - (target OD value / No NK OD value)}*100
[0207] As a result, we observed that as the number of NK92 cells increased, the degree of liver cancer cell death increased (Figure 9c). These results suggest that PTGFRN acts as an immune checkpoint molecule in cancer cells, inhibiting NK cell-mediated apoptosis, thereby providing cancer cells with the ability to evade the host immune system.
[0208]
[0209] 6-6. Analysis of changes in signaling molecules due to PTGFRN deficiency in liver cancer
[0210] Using the knocked-down cells as in Example 6-3 above, the expression of FAK and Src, which are important key signaling molecules in cancer metastasis, and B7-H3, known as an immune checkpoint molecule, was confirmed.
[0211] The knocked-down cells were harvested and washed twice with phosphate buffer (pH 7.4), and then lysed using RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Deoxycholate). The cells were centrifuged at 4°C and 12,000 rpm for 30 minutes, and the supernatant was mixed with 5X sample buffer to prepare a protein sample. Afterwards, the samples were separated on an 8-10% SDS-PAGE gel and transferred to a nitrocellulose membrane for Western blotting. Blocking was performed using 5% skim milk powder, and each target antibody, rabbit anti-PTGFRN polyclonal antibody (abcam, 97567), rabbit anti-B7-H3 polyclonal antibody (sinobiological, 11188-RP02), rabbit anti-FAK polyclonal antibody (Cell Signaling Technology, 3285), rabbit anti-p-FAK polyclonal antibody (CST, 3283), rabbit anti-Src monoclonal antibody (CST, 2109), rabbit anti-p-Src monoclonal antibody (CST, 6943), rabbit anti-GAPDH polyclonal antibody (CSB, PA00025A0Rb), was mixed in 5% BSA and reacted at 4°C for 16 hours. After washing three times with 0.1% TBST (Tris-Buffered Saline, 0.1% tween) for 10 minutes each, the sample was reacted with anti-rabbit IgG-HRP (1:12,000) at room temperature for one hour, and the target protein was confirmed using an ECL detection kit (Advansta) (Fig. 10).
[0212] As a result, the decrease in PTGFRN decreased the expression of B7-H3, an immune checkpoint regulatory molecule, and decreased the expression of p-FAK and p-Src, which are FAK signaling pathways. These results indicate that PTGFRN regulates cancer cell migration and invasiveness through the FAK signaling pathway.
[0213]
[0214] 6-7. Measurement of cis and trans bonds between PTGFRN in the cell membrane
[0215] If PTGFRN expressed on the cell membrane contributes to the formation of clusters between cells, PTGFRN expressed on cancer cells in the blood may help cancer cell growth, survival, and immune evasion. To observe this, 2.5 x 10 cells per well were seeded in a 6-well plate. 5 After dividing the cells, the next day, 12 μg of PEI, pcDNA3.1(+)PTGFRN-FLAG vector, and pcDNA3.1(+)-PTGFRN-myc vector were diluted together to 4 μg each in TOM (Welgene) and reacted at room temperature for 5 minutes. After that, the diluted PEI solution and the diluted vector solution were mixed and reacted at room temperature for 20 minutes, and then treated together with one HEK293FT cell and cultured for 24 hours in an incubator at 37°C and 5% CO2. In addition, pcDNA3.1(+)PTGFRN-FLAG vector and pcDNA3.1(+)-PTGFRN-myc vector were each prepared and reacted separately in two HEK293FT cell wells. After 24 hours, the culture medium was replaced and cultured for an additional 48 hours, and a cell lysis buffer was treated in the same manner as in Example 4 to prepare a cell lysate. Using BCA (Thermo), 50 μg of each cell lysate was prepared, and each lysate was immunoprecipitated using mouse anti-FLAG monoclonal antibody, rabbit anti-myc tag monoclonal antibody, and mouse 63-D7 antibody, followed by analysis by Western blotting with anti-FLAG monoclonal antibody and rabbit anti-myc tag monoclonal antibody.
[0216] As a result, both FLAG and myc tags were detected in the cell lysates co-expressing PTGFRN (Fig. 11a). However, when each was transfected singly and then mixed for immunoprecipitation, FLAG-tagged PTGFRN was not detected in PTGFRN immunoprecipitated with anti-myc antibody, and myc-tagged PTGFRN was not detected in PTGFRN immunoprecipitated with anti-FLAG antibody (Fig. 11b). Therefore, this confirms that PTGFRN interacts with each other in a cis- rather than a trans- form on the cell membrane.
[0217]
[0218] 6-8. Analysis of PTGFRN binding substances in the cell membrane
[0219] To find other proteins that bind to PTGFRN in the cell membrane, SNU449 cell lysates were prepared as in Example 4, and then immunoprecipitated using mouse anti-PTGFRN monoclonal antibody, mouse 63-D7 monoclonal antibody, mouse anti-SLC3A2 monoclonal antibody, and mouse anti-B7-H3 monoclonal antibody. Western blotting was performed using mouse anti-PTGFRN monoclonal antibody (α-PTGFRN). As a result, it was confirmed that PTGFRN binds to SLC3A2 (CD98hc) and B7-H3 (CD276) (Fig. 11c).
[0220] Since B7-H3 is known to be an immune checkpoint regulator in cancer cells, to verify the interaction between B7-H3 and PTGFRN once again, HEK293FT cells were seeded at 2.5 X 10 per well in a 6-well plate. 5After dividing the cells into 10 cells, the next day, 12 μg of PEI, PTGFRN vector with myc tag (pcDNA3.1(+)PTGFRN-myc) and PTGFRN vector with FLAG tag (pcDNA3.1(+)-B7-H3-FLAG) were diluted to 4 μg each in TOM (Welgene, Gyeongsan, Korea) and reacted at room temperature for 5 minutes. Afterwards, the diluted PEI solution and the diluted vector solution were mixed and reacted at room temperature for 20 minutes, treated to transfect HEK293FT cells, and cultured in an incubator at 37°C and 5% CO2 for 24 hours. After 24 hours, the culture medium was replaced with fresh medium and cultured for an additional 48 hours, and then the cell lysate was prepared as in Example 4. Using BCA (Thermo Fischer Scientific), 50 μg of each cell lysate was prepared and immunoprecipitated with anti-FLAG, anti-B7-H3, anti-myc, and 63-D7. The immunoprecipitates were detected with anti-myc and anti-FLAG antibodies. PTGFRN was detected in the immunoprecipitate with the anti-FLAG antibody, and B7-H3 was detected in the immunoprecipitate with the anti-myc antibody. This indicates that PTGFRN and B7-H3 physically bind and interact with each other (Fig. 11d). These results suggest that PTGFRN is involved in immune regulation through B7-H3, a known immune checkpoint regulatory molecule.
[0221]
[0222] Example 7. Analysis of adhesiveness, cancer stemness, and clonogenicity of 63-D7-positive liver cancer cells.
[0223] To analyze how the antigen PTGFRN of 63-D7 affects the adhesion of hepatoma cells, Huh7 and HepG2 cells were sorted into 63-D7 positive and negative using magnetic beads with 63-D7 antibody.
[0224] For sorting, 63-D7-biotin antibody was separated using Neutravidin-conjugated magnetic beads (Thermo Fishcer Scientific) according to the manufacturer's protocol. Cells bound to the antibody were separated as 63-D7(+), and cells that did not bind were separated as 63-D(-). Next, 12-well plates were coated with Matrigel and blocked in serum-free DMEM / F12 medium containing 5% BSA at 37°C for at least 1 hour. 63-D7(+) and 63-D7(-) hepatoma cells were seeded at 10 per well. 5 The plates were inoculated with 63-D7 cells and incubated at 37°C for 6 hours. To remove non-attached cells, the plates were washed with PBS (pH 7.4). The adherent cells were stained with 0.5% crystal violet (Sigma-Aldrich) in 2% ethanol at room temperature for 30 minutes, and the stained cells were dissolved in 0.1% SDS and the absorbance was measured at 570 nm. As a result, the adhesion of 63-D7(+) Huh7 cells increased by 43% compared to 63-D7(-) Huh7 cells, and the adhesion of 63-D7(+) HepG2 cells increased by 245% compared to 63-D7(-) HepG2 cells, suggesting that 63-D7-positive hepatoma cells have significantly better adhesion to the extracellular matrix than do negative hepatoma cells (Fig. 12a, Fig. 12b).
[0225] Meanwhile, to observe whether 63-D7 antigen-positive cancer cells have cancer stemness and are related to cancer recurrence and drug resistance, tumorspheres that induce cancer stemness were cultured. To generate tumorspheres, adherent Huh7 hepatoma cells were detached with trypsin-EDTA (Welgene, Daegu, Korea), filtered through a 40 μm strainer, and centrifuged at 1500 rpm for 3 min at room temperature. The cells were seeded at 2.1 x 10 on very low-adherence plates (Corning, SEOUL, KOREA).3 cells / cm 2 and cultured in DMEM / F12 medium (Corning) supplemented with 20 ng / ml fibroblast growth factor 2 (FGF2, R&D Systems, Seoul, Korea), 20 ng / ml epidermal growth factor (EGF, PeproTech, Seoul, Korea), and 1 x B27 supplement (Life Technologies). The medium was changed every 3 days, and cultured for at least 9 days. The expression of CD133, CD44, and EpCAM, known as representative liver cancer stem cell markers, and PTGFRN, a 63-D7 antigen, was analyzed by flow cytometry in the same manner as in Example 3. As a result, in tumor cell cultures with increased cancer stem cell abundance, cancer stem cell-positive markers CD133, CD44, and EpCAM increased by approximately 33%, 43%, and 59%, respectively, compared to adherent cells, and the binding of 63-D7 also increased by 61% (Fig. 12c, Fig. 12d). These results suggest that PTGFRN, a 63-D7 antigen, acts as a novel liver cancer stem cell marker.
[0226] To further analyze whether 63-D7-positive liver cancer cells exhibit liver cancer stemness, a clonogenic survival experiment showing cancer stemness was performed using liver cancer cells sorted with 63-D7 in the same manner as above, as in Example 6-2. As a result, an increase in clonogenicity was observed in Huh7 by 492% (Figs. 12e and 12f) and in HepG2 by 56% (Figs. 12g and 12h). These results suggest that 63-D7-positive liver cancer cells exhibit significant cancer stemness and have cancer stem cell properties with excellent clonogenic survival ability compared to 63-D7-negative liver cancer cells.
[0227]
[0228] Example 8. Internalization analysis after 63-D7 treatment in liver and pancreatic cancer cells.
[0229] When treated with antibodies, the internalization of antibodies into cancer cells is a key prerequisite for the development of anticancer antibody therapeutics using antibody-drug conjugates (ADCs). To confirm the internalization of monoclonal antibody 63-D7 into various cancer cells, flow cytometry analysis was performed.
[0230] Cells were detached with 0.05% Trypsin-EDTA (Welgene) and neutralized with cell culture medium containing 10% fetal bovine serum (FBS; VWR, PA, USA). Then, the cells were passed through a 40 μm strainer to prepare single cells. Each single cell was prepared at approximately 1 × 10 per ml. 5After mixing each cell with PBA (1% bovine serum albumin, 0.02% NaN3 in PBS), the antibody 63-D7 was reacted at 4°C for 30 minutes. To induce the internalization of the antibody, the cells were washed once with PBA, and then suspended in 100 μl of culture medium and reacted at 37°C for 30 minutes to allow cell membrane internalization. After washing once with PBA, the cells were reacted with anti-mouse IgG-Alexa flour 488 (Invitrogen) corresponding to the primary antibody at 4°C for another 20 minutes. After washing twice with PBA, the antibody reaction was analyzed for PI (propidium iodide)-negative cells using FACSCalibur and Cell Quest software (BD sciences). When comparing the fluorescence intensity of monoclonal antibody 63-D7 bound to the cell surface at 4°C and the degree of fluorescence intensity of 63-D7 when reacted at 37°C by flow cytometry, it can be seen that the binding of monoclonal antibody 63-D7 is significantly reduced in human hepatoma cells Huh7, HepG2, SNU387, SNU449 and human pancreatic cancer cells BxPC3, SNU213 (Fig. 13a, Fig. 13b). This means that the 63-D7 antibody bound to the cancer cell surface at 4°C is internalized into the cells by cell activity at 37°C, thereby reducing the binding on the surface, and suggests that 63-D7 is an antibody that can be applied to the development of antibody therapeutics using ADC.
[0231]
[0232] Example 9. Cytotoxicity of drug-conjugated 63-D7 antibody in hepatoma cells
[0233] Through the previous Example 8, it was confirmed that the 63-D7 antibody, which has a mouse IgG1 constant region, binds to the surface of liver cancer cells and is internalized into the cells at 37°C. Based on the above characteristics, when an anticancer drug is conjugated to the 63-D7 antibody, it was assumed that the drug delivered via the 63-D7 antibody would exhibit cytotoxicity in cancer cells, and an experiment was conducted to confirm this.
[0234] In the experiment, drug-conjugated mouse IgG Fc region-specific secondary antibodies [anti-mouse IgG (Fc Specific) antibody-drug conjugates (ADCs)] were used. Specifically, α-mFc-CL-DMDM (AM-102DD, Moradec, USA) antibody conjugated with duocarmycin, a DNA alkylation agent, and α-mFc-CL-MMAF (AM-102AF, Moradec) antibody conjugated with monomethyl auristatin, a tubulin polymerization inhibitor, were used. First, 5,000 Huh7 cells were dispensed into each well of a 96-well plate (SPL) using RPMI-1640 (Biowest, France) medium containing 10% FBS and cultured for 24 hours. The next day, the existing culture medium was removed, and 63-D7 antibody or mouse IgG isotype control (Invitrogen, 31903) diluted in culture medium at various concentrations was dispensed into each well at 100 nM, 10 nM, 1 nM, 0.1 nM, and 0.01 nM, and the antibody was allowed to bind to the cell surface for 10 minutes at 37℃. After that, the drug-conjugated secondary antibody at a concentration of 12.7 nM was diluted in culture medium, the primary antibody was removed, and the antibody was dispensed into each well. After culturing the cells for 48 hours at 37℃ under 5% CO2 conditions, Cell Counting Kit-8 (CCK-8, K1018, APExBIO, USA) was used to determine cell viability. 10 μl of CCK-8 was added to each well, reacted for 3 hours, and the absorbance at OD450 nm was measured using a plate reader.
[0235] As a result, it was confirmed that when 100 nM 63-D7 antibody was treated with α-mFc-CL-DMDM ADC, cell viability decreased by 40%, and when 10 nM 63-D7 antibody was treated, cell viability decreased by 20% (Fig. 14a). When the same experiment was performed using α-mFc-CL-MMAF, the viability of liver cancer cells decreased by 40% at 100 nM and by 20% at 10 nM (Fig. 14b). However, the viability of cells treated with mouse-derived isotype antibodies did not show a significant change. This proved that the drug-conjugated secondary antibody used in the experiment specifically binds to the mouse Fc region, enters the cell together with the mouse antibody 63-D7, and induces cytotoxicity.
[0236] Therefore, the 63-D7 antibody is internalized into hepatoma cells, and based on this characteristic, it can effectively deliver drugs into PTGFRN-expressing hepatoma cells, thereby exhibiting anticancer effects. These results suggest that an ADC strategy using the 63-D7 antibody can induce apoptosis in hepatoma and pancreatic cancer cells.
[0237]
[0238] Example 10. Analysis of 63-D7 antigen in blood cancer cells from liver cancer patients.
[0239] 10-1. Detection of 63-D7-positive blood cancer cells in the blood of liver cancer patients using immunocytochemical methods.
[0240] We confirmed that PTGFRN promotes survival, migration, invasion, cell adhesion, and immune evasion of hepatocellular carcinoma (HCC) cells, which are biological characteristics of circulating cancer cells important for metastasis (Figs. 5 to 9). Therefore, we hypothesized that PTGFRN could serve as a surface marker for detecting circulating cancer cells in HCC patients, and indeed, this possibility was confirmed in preliminary experiments detecting circulating cancer cells (Figs. 1b and 1c).
[0241] To efficiently detect circulating cancer cells in HCC patients, we chose a strategy of removing red blood cells, then further removing CD45-positive cells by a CD45 depletion protocol, and analyzing the remaining cells (Fig. 15c). Specifically, peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of healthy donors, hepatitis patients, or HCC patients by Ficoll-Paque Plus (GE Healthcare, Seoul, Korea) gradient centrifugation within 6 h after collecting the blood of HCC patients. PBMCs were washed with PBS containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA and resuspended in 1 × 10 8cells / mL. Enrichment of circulating cancer cells by removal of CD45-positive cells from these leukocyte lineages was performed using a Human CD45 Deletion Kit (EasySep®, Stem Cells Technologies, Vancouver, BC, Canada) according to the provided protocol. First, anti-CD45 antibody was added to the cell suspension and reacted at room temperature for 15 minutes. Dextran-coated magnetic nanoparticles were reacted with the cells for 10 minutes at room temperature, and the cell suspension was placed in an EasySep® big easy magnet (StemCell Technologies, Vancouver, Canada) for 10 minutes at room temperature. The unbound cell fraction was then transferred to a clean tube and collected. The collected cells were centrifuged at 3,560 × g for 5 minutes, resuspended in 400 μl of RPMI1640 medium, divided into eight fractions, and finally seeded onto glass slides coated with 0.1 μg / ml of poly-L-lysine. To induce spontaneous binding of cells to glass slides, cells were incubated at room temperature for 2–4 hours. Unbound cells were washed with PBS (pH 7.4) before fixation. Bound cells were fixed in 3.7% paraformaldehyde (PFA) and stored in the refrigerator before analysis by confocal microscopy.
[0242] To test the sensitivity and specificity of the CD45-positive leukocyte depletion method, increasing numbers of Huh7 cells were added to PBMCs, and the CD45 depletion protocol described above was applied to remove CD45-positive cells. The number of remaining 63-D7-positive Huh7 cells was measured after blocking with 10% normal horse serum. At this time, Huh7 was stained by immunocytochemical method using Dylight488-conjugated 63-D7 labeled with 63-D7 antibody using Dylight488-conjugation Kit (Vector laboratories, Burlingame, CA, USA). The linear regression of the number of detected Huh7 cells versus the number of spiked Huh7 cells had an R of 0.9801. 2 The average recovery rate of Huh7 cells was approximately 72%, showing that more than 70% of cells can be detected using this method (Fig. 15b).
[0243] To confirm the complete removal of CD45, double staining of 63-D7 and CD45 was performed. CD45-depleted cells were fixed with 3.7% PFA, blocked with 10% normal horse serum, and then reacted with Dylight 649-conjugated anti-mouse IgG (Vector Laboratories) and Dylight 488-conjugated 63-D7. After washing with PBS, nuclei were stained with DAPI (4,6-diamidino-2-phenylindole). Fluorescent signals were detected using a Leica TCS SP5 confocal microscope (Leica Microsystems, Seoul, Korea). As a result, all 63-D7-positive cells were confirmed to be CD45-negative (lower panel of Fig. 15c, Table 3). The expression profile of EMT markers in 63-D7+ nucleated CTCs from HCC patients by double immunofluorescence staining is shown in detail in Table 3 below.
[0244] MarkersPrimary HCCSecondary HCCPatients with marker-positive CTCsMarker-positive CTCsPatients with marker-positive CTCsMarker-positive CTCsDAPI+ (63-D7-)NDND22 / 22 (100%)453 / 3307(13.7%)63-D7+ CD45+0 / 20 (0.0%)0 / 123 (0.0%)0 / 2 (0.0%)0 / 24(0.0%)63-D7+ MVP+16 / 20 (80.0%)100 / 363 (27.5%)5 / 5(100%)35 / 147(23.8%)63-D7+ HSA+3 / 4 (75.0%)29 / 118 (24.6%)2 / 2(100%)21 / 85(24.7%)63-D7+ PanCK+0 / 4 (0.0%)0 / 104 (0.0%)0 / 1(0%)0 / 24(0%)63-D7+ E-cadherin+0 / 1 (0.0%)0 / 18 (0.0%)NDND63-D7+ EpCAM+20 / 20 (100%)46 / 331 (13.9%)4 / 4(100%)19 / 111(17.1%)63-D7+ Vimentin+7 / 8 (100%)43 / 180 (23.9%)NDND63-D7+ Twist+6 / 10 (60.0%)6 / 189 (3.2%)NDND63-D7+ ZEB1+3 / 5 (60.0%)3 / 60 (5.0%)NDND
[0245]
[0246] Next, blood samples from 21 healthy volunteers and 95 HCC patients (53 primary HCC patients and 42 secondary HCC patients) were collected using the same method as described above. CD45-positive cells were removed, and the remaining cells were attached to slides and analyzed using a confocal microscope. The number of all 63-D7-positive circulating cancer cells in the blood of patients with liver cancer (HCC, HCC(meta)), normal subjects (Normal), and hepatitis patients is shown in Table 4 below.
[0247] NumberCancerSexAgePBMC(X107)blood(ml)total 63-D763-D7 / 7.5ml63-D7 / ml1HCCM693.751121141.902HCCF631.131015111.503HCCF621.059.428222.984HCCM653.21061466.105HCCM642.3 510.644314.156HCCM542.4310320.307HCCM683.541038293.808HCCM64210.214101.379HCCM731.681033253.3010HCCM542.08815141.8811H CCF601.4810.122162.1812HCCF622.2310.426192.5013HCCF453.639.424192.5514HCCM601.8710.1650.5915HCCM721.510.225182.4516HCC M451.45820192.5017HCCM681.375928233.1118HCCM451.459.839303.9819HCCM480.59.8650.6120HCCM590.8259.818141.8421HCCM56191311 1.4422HCCM581.0751030233.0023HCCF582.510.440293.8524HCCF620.75918152.0025HCCM590.875828263.5026HCCM551.125943364.7827H CCM751.5110.514101.3328HCCM651.37510110.1028HCCM501.5759.523182.4230HCCM411.810.341303.9831HCCM451.510.118131.7832HCCM7 21.551033253.3033HCCM751.491013101.3034HCCM571.510.565466.1935HCCM641.158.636314.1936HCCM602.7510.532233.0537HCCM592.5 51030233.0038HCCM541.5924202.6739HCCM381010.526192.4840HCCM560.648.527243.1841HCCM686.439.222182.3942HCCF441.231034263.<h2 style=";text-align:left;direction:ltr">4043HCCM660.9610.524172.2944HCCM491.068.350456.0245HCCM782.110.414101.3546HCCM392.510.520141.9047HCCF602.051129202.6448HCCM5 50.7911530.4549HCCM58110.725182.3450HCCM591.3110.41181.0651HCCM574.2510.61391.2352HCCM561.358.817141.9353HCCM391.259.2320.33 54HCC(meta)F681.29.563506.6355HCC(meta)M575.251056425.6056HCC(meta)F6839.836283.6757HCC(meta)M572.3810.532233.0558HCC(meta)M623.19.528222.9559HCC(meta)M590.8259.816121.6360HCC(meta)F441.375924202.6761HCC(recu)M671.138.544395.1862HCC(meta)F610.758151 41.8863HCC(meta)F562.159.524192.5364HCC(meta)M588.410.415111.4465HCC(meta)F672.75865618.1366HCC(meta)M500.61817015921.2567HC C(meta)F381.259.570557.3768HCC(meta)M660.8131140273.6369HCC(meta)M761.1310.550364.7670HCC(meta)M663.2107052.57.0071HCC(meta) F701.311558380.550.7272HCCM571.5310.510071.439.5273AGMLM335939334.3374HCC(meta)M0.8510.55539.35.2475HCC(meta)F0.558.5125110. 314.7176HCC(meta)M0.910.5141100.713.4377HCC(meta)F1.3899075.010.0078HCC(meta)M1.5510164123.016.4079HCC(meta)M1.138.39182.210.<h2 style=";text-align:left;direction:ltr">9680HCC(meta)M2.110.513596.412.8681HCC(meta)M2.310.3162118.015.7382HCC(meta)M1.759.512397.112.9583HCC(meta)M1.859.3159128.217.1084HCC(meta)M1.71011888.511.8085HCC(meta)F1.9510158118.515.8086HCC(meta)M1.4710.5143102.113.6287HCC(meta)F2.1510.513999.313.2488HCC(meta)F210 .712285.511.4089HCC(meta)M1.910188141.018.8090HCC(meta)M210.57251.4 6.8691HCC(meta)M1.751013299.013.2092HCC(meta)M1.358.5160141.218.829 3HCC(meta)M2.258.510693.512.4794HCC(meta)M1.99.7140108.214.4395HCC(meta)M0.89.5130102.613.68NumberNormalSexAgePBMC(X107)blood(ml)total 63-B663-B6 / 7.5ml63-B6 / ml1NormalM522.510.8000.002NormalM632.37510.3430.393NormalM541.87510.1210.204NormalM313.5751 0000.005NormalM282.910.8000.006NormalM321.7510.8000.007NormalF25110.2320.298NormalF361.338.2000.009NormalF260.838 000.0010NormalM302.258.3000.0011NormalF232.58.3110.1212NormalM353.758.2220.2413NormalM3328.3000.0014NormalM282.25 8.4000.0015NormalM331.58.4000.0016NormalM292.58000.0017NormalF2338.5000.0018NormalM541.47.5000.0019NormalM2718000.0020NormalF251.858.3000.0021NormalM471.27.3000.0022Chronic hepatitisM451.038.7000.0023Chronic hepatitisM540.6258.5000.0024CirrhosisM611.6258.2000.0025CirrhosisF710.88000.0026Acute hepatitisF617.58.3000.00.
[0248]
[0249] Although a few 63-D7-positive cells were detected in 5 of 21 normal adults, the measured cell numbers were very rare (≤ 0.39 cells / ml) (Table 4). When blood cells from HCC patients were stained with 63-D7 and other antibodies, 13.7% of cells were 63-D7-negative and DAPI-positive, and approximately 14% of circulating cancer cells were not detected by 63-D7 (Fig. 15c, upper panel, Table 3). When cells isolated from HCC patients were stained with 63-D7 and CD45 antibodies, all 63-D7-positive cells were CD45-negative (Fig. 15c, lower panel, Table 3), suggesting that 63-D7 can detect approximately 86% of CD45-negative and DAPI-positive circulating cancer cells. The size of 63-D7-positive circulating cancer cells was heterogeneous, ranging from 18 μm to 40 μm, and they had hyperchromatic nuclei and a high nuclear-to-cytoplasmic ratio (Figs. 16a to 16c). 63-D7-positive circulating cancer cells were detected in all HCC patients, and 92 of 95 patients (approximately 97%) had a higher cell count than normal adults (Fig. 17, Table 4) (p<0.0001). The number of cells isolated from HCC patients ranged from 0.1 to 50.72 cells per ml, with an average of 6.13 cells per ml (Table 4). 63-D7-positive circulating cancer cells were not found in patients with chronic hepatitis or cirrhosis (Table 4), suggesting that they are circulating cancer cells resulting from cancer development, not inflammatory cells caused by hepatitis or other diseases.
[0250] The associations between 63-D7 and clinical pathological variables are shown in Table 5 below.
[0251] VariableCategoryTotal(n=53)63-D7<2.45(n=26)63-D7 ≥2.45(n=27)p-valueage1:≤60yrs33 (62.26)16 (61.54)17 (62.96)0.91482:>60yrs20 (37.74)10 (38.46)10 (37.04)sex1:M44 (83.02)23 (88.46)21 (77.78)0.46722:F9 (16.98)3 (11.54)6 (22.22)Edmondson grade1:1+248 (90.57)23 (88.46)25 (92.59)0.66872:3+45 (9.43)3 (11.54)2 (7.41)Tumor_size1:<328 (52.83)14 (53.85)14 (51.85)0.86442:3~518 (33.96)8 (30.77)10 (37.04)3:≥57 (13.21)4 (15.38)3 (11.11)Microvessel invasion017 (32.08)14 (53.85)3 (11.11)0.0009136 (67.92)12 (46.15)24 (88.89)Portal vein invasion051 (96.23)25 (96.15)26 (96.3)1.000012 (3.77)1 (3.85)1 (3.7)Bile duct invasion052 (98.11)25 (96.15)27 (100)0.490611 (1.89)1 (3.85) Intrahepatic metastasis045 (84.91)24 (92.31)21 (77.78)0.250118 (15.09)2 (7.69)6 (22.22)Multicentric occurrence047 (88.68)23 (88.46)24 (88.89)1.000016 (11.32)3 (11.54)3 (11.11)Serosa invasion051 (96.23)25 (96.15)26 (96.3)1.000012 (3.77)1 (3.85)1 (3.7)Pathologic T stage (modified UICC, 2000)1:pT1+pT219 (35.85)14 (53.85)5 (18.52)0.00732:pT3+pT434 (64.15)12 (46.15)22 (81.48)Pathologic T stage (AJCC, 2010)1:pT1+pT251 (96.23)25 (96.15)26 (96.3)1.00002:pT3a2 (3.77)1 (3.85)1 (3.7)Etiology1:HBV48 (90.57)22 (84.62)26 (96.3)0.19172:HCV+other5 (9.43)4 (15.38)1 (3.7)Child-Pugh class1:A50 (94.34)24 (92.31)26 (96.3)0.61042:B+C3 (5.66)2 (7.69)1 (3.7)Clinical Stage (AJCC)1:1+251 (96.23)25 (96.15)26 (96.3)1.00002:3a2 (3.77)1 (3.85)1 (3.7)Clinical stage (UICC)1:1+220 (37.74)15 (57.69)5 (18.52)0.00332:3+433 (62.26)11 (42.31)22 (81.48)Milan_Criteria040 (75.47)20 (76.92)20 (74.07)0.8096113 (24.53)6 (23.08)7 (25.93)AFP(ng / ml)1:≤8.128 (52.83)15 (57.69)13 (48.15)0.48652:>8.125 (47.17)11 (42.31)14 (51.85)PIVKA II(mAU / ml)1:<4031 (58.49)13 (50)18 (66.67)0.21832:≥4022 (41.51)13 (50)9 (33.33).
[0252]
[0253] In a clinicopathological analysis of 53 patients with primary hepatocellular carcinoma, there was a statistically significant correlation between the number of 63-D7-positive circulating tumor cells and the advanced tumor stage group, with microvascular invasion, pathological stage, and clinical stage, indicating that patients with 63-D7-positive tumor cells had microvascular invasion and advanced to a worse stage in pathological and clinical stages (Table 5).
[0254] This means that the higher the number of 63-D7-positive circulating cancer cells, the worse the pathological and clinical condition. When the patient group was divided into primary HCC and secondary metastatic and recurrent HCC, the number of 63-D7-positive circulating cancer cells was more increased in the secondary metastatic and recurrent HCC patient group than in the primary HCC patient group (Fig. 17, Table 4) (p<0.0001). Therefore, the number of 63-D7-positive circulating cancer cells (normal vs. primary HCC = ≤0.39 vs. 2.54 cells / ml) is an excellent diagnostic marker for diagnosing primary HCC patients (Table 4), and it is an excellent diagnostic marker closely related to disease progression, with the number further increasing in metastasis or recurrence (mean 10.7 cells / ml) (Table 4).
[0255]
[0256] 10-2. Characterization of 63-D7-positive blood cancer cells by double staining.
[0257] To further characterize 63-D7-positive blood cancer cells, cells were simultaneously stained with 63-D7 and various antibodies.
[0258] To double stain circulating cancer cells with 63-D7 and various surface markers, CD45-depleted cells were fixed with 3.7% PFA, blocked with 10% normal horse serum, and then reacted with anti-MVP (Aviva systems, San Diego, CA, USA), anti-CD44 (BD bioscience, Seoul, Korea), anti-CD90 (BD bioscience), Alexa 555-conjugated anti-EpCAM (BD Biosciences), Alexa 555-conjugated anti-E-cadherin (Cell Signaling Technology, Beverly, MA, USA), and anti-HSA (Novus, Litteleton, CO, USA), followed by further reaction with Dylight 650-conjugated anti-rabbit IgG (Thermo Fischer Scientific), and finally, Dylight 488-conjugated 63-D7, and stained as in Example 10-1. For double staining of Dylight 488-conjugated 63-D7 and intracellular markers, CD45-depleted cells were fixed and permeabilized with 0.1% Triton X-100 before blocking and reacted with anti-vimentin (Santa Cruz Biotechnology), anti-Twist1 (AbCAM, Cambridge, UK), anti-ZEB1 (AbCAM), or phycoerythrin-conjugated anti-panCK antibody (BD biosciences, San Jose, CA, USA). Cells were then incubated with Dylight 650-conjugated anti-rabbit IgG (Thermo Fischer Scientific) depending on the conjugation status of the primary antibody and finally reacted with Dylight 488-conjugated 63-D7, and the fluorescence signals were detected and analyzed using a Leica TCS SP5 confocal microscope (Leica Microsystems).
[0259] In our previous study, we found that cell surface MVP (major vault protein) was detected in approximately 90% of circulating cancer cells from HCC patients and that its expression was further increased in metastatic cancer cells (Lee, et al., Sci Rep. vol. 7, 13201, 2017). Therefore, we first simultaneously stained circulating cancer cells with 63-D7 and MVP antibodies. As a result, approximately 28% (100 / 363) of 63-D7-positive circulating cancer cells were MVP-positive in primary HCC patients, and approximately 24% (35 / 147) of 63-D7-positive circulating cancer cells were MVP-positive in secondary HCC patients (Fig. 16a, Table 3). In 63-D7 / HSA staining, approximately 25% (50 / 203) of 63-D7-positive circulating cancer cells were HSA-positive in both primary and secondary HCC patients (Fig. 16a, Table 3). In 63-D7 / E-cadherin staining, all circulating cancer cells were E-cadherin-negative (0 / 18) in all primary HCC patients (Fig. 16b, Table 3). In 63-D7 / panCK (pan-cytokeratin) staining, all circulating cancer cells were panCK-negative in both primary (0 / 104) and secondary HCC patients (0 / 24) (Fig. 16a, Table 3). In 63-D7 / EpCAM staining, approximately 15% (67 / 442) of 63-D7-positive cells were EpCAM-positive in both primary and secondary HCC patients (Fig. 16b, Table 3). Thus, well-known epithelial markers such as PanCK or E-cadherin were not expressed in PTGFRN-positive circulating cancer cells recognized by 63-D7, regardless of whether they were primary or secondary metastatic / recurrent cancers. This suggests that 63-D7-positive circulating cancer cells are at least not epithelial circulating cancer cells.
[0260] Therefore, to determine whether 63-D7-positive circulating cancer cells exhibit a mesenchymal phenotype, representative mesenchymal markers Vimentin, Twist, and ZEB1 were observed in primary HCC patients. Approximately 24% (43 / 180) of 63-D7-positive circulating cancer cells were vimentin-positive (Fig. 16c, Table 3). In addition, Twist (3.2%, 6 / 189) and ZEB1 (5%, 3 / 60) positivity were also observed in small fractions in 63-D7-positive circulating cancer cells (Fig. 16c, Table 3). Therefore, although 63-D7-positive circulating cancer cells have a significantly predominant mesenchymal phenotype when comparing the proportions of epithelial and mesenchymal phenotypes, it can be seen that in most cases, they are a partially intermediate-stage cell population in which the distinction between epithelial and mesenchymal phenotypes is unclear.
[0261]
[0262] 10-3. Characterization of 63-D7-positive blood cancer cells by triple staining
[0263] To further analyze the expression patterns of epithelial and mesenchymal phenotype markers in 63-D7-positive circulating cancer cells from primary and secondary HCC patients, triple fluorescence staining for 63-D7 / EpCAM / vimentin was performed using CD45-depleted circulating cancer cells, using the epithelial representative marker EpCAM and the mesenchymal representative marker Vimentin (Fig. 18a, Table 6). The results of the triple fluorescence staining are specifically presented in Table 6 below.
[0264] MarkersPrimary HCCSecondary HCCPatients with marker-positive CTCsMarker-positive CTCsPatients with marker-positive CTCsMarker-positive CTCs63-D7 + EpCAM + Vimentin +7 / 21 (33.3%)47 / 518 (9.1%)3 / 30 (0.1%)3 / 933 (0.3%)63-D7 + EpCAM + Vimentin - 2 / 21 (9.5%)3 / 518 (0.6%)0 / 30 (0.0%)0 / 933 (0.0%)63-D7 + EpCAM - Vimentin + 18 / 21 (85.7%)229 / 518 (44.2%)27 / 30 (90.0%)255 / 933 (27.3%)63-D7 + EpCAM - Vimentin - 19 / 21 (90.5%)239 / 518 (46.1%)30 / 30 (100%)675 / 933 (72.3%)MVP + EpCAM + Vimentin + 0 / 5 (0.0%)0 / 144 (0.0%)0 / 9 (0.0%)0 / 304 (0.0%)MVP + EpCAM + Vimentin - 0 / 5 (0.0%)0 / 144 (0.0%)0 / 9 (0.0%)0 / 304 (0.0%)MVP + EpCAM - Vimentin + 3 / 5 (60.0%)67 / 144 (46.5%)9 / 9 (100.0%)151 / 304 (49.7%)MVP + EpCAM - Vimentin - 4 / 5 (80.0%)77 / 144 (53.5%)9 / 9 (100.0%)153 / 304 (50.3%)
[0265]
[0266] For triple staining of 63-D7, Vimentin, and EpCAM, CD45-depleted cells were fixed and permeabilized with 0.1% Triton X-100 before blocking and reacted first with anti-Vimentin antibody (Santa Cruz Biotechnology). Cells were then reacted with Dylight 650-conjugated anti-rabbit IgG (Thermo Scientific), Alexa 555-conjugated anti-EpCAM (Cell Signaling Technology), and Dylight 488-conjugated 63-D7, with Ca 2+ and Mg 2+ Cells were washed four times with PBS containing . Nuclei were stained with DAPI, and fluorescence signals were detected using a confocal microscope (Leica Microsystems).
[0267] As a result, 63-D7 + EpCAM + Vimentin + Triple-positive blood cancer cells were present in 9.1% (47 / 518) of primary HCC patients, while in 0.3% (3 / 933) of secondary HCC patients. 63-D7, representing epithelial cells + EpCAM + Vimentin - Blood cancer cells were present in 0.6% (3 / 518) of primary HCC patients, but not in secondary HCC patients (0 / 933). 63-D7, a representative mesenchymal cell type, was present. + EpCAM - Vimentin + Blood cancer cells were present in 44.2% (229 / 518) of primary HCC patients, compared to 27.3% (255 / 933) of secondary HCC patients (Fig. 18a, Table 6).
[0268] Thus, 0.6% of 63-D7-positive circulating cancer cells in primary HCC had an epithelial phenotype, whereas 53.3% (9.1% + 44.2%) had semimesenchymal (both EpCAM and vimentin positive) and mesenchymal (vimentin positive) phenotypes. Interestingly, 63-D7 single-positive circulating cancer cells with a partial or intermediate phenotype lacking neither EpCAM nor Vimentin were 46.1% in primary HCC patients and a whopping 72.3% (675 / 933) in secondary HCC patients. Furthermore, this intermediate phenotype was observed in all investigated secondary HCC patients (30 / 30 patients), suggesting that the intermediate phenotype expressing only 63-D7 is a key circulating cancer cell marker in patients with metastatic recurrent HCC (Table 6).
[0269] Because a previous study reported that 51.3% of MVP-positive circulating cancer cells were MVP-single positive in MVP / EpCAM / Vimentin triple staining (Lee, Joh et al. 2017), we performed MVP / EpCAM / Vimentin triple staining using the same method. When MVP-single positive circulating cancer cells were classified into primary and secondary HCC, MVP-single positive circulating cancer cells were 53.5% in primary HCC patients and 50.3% in secondary HCC patients (Table 6). In addition, MVP-single positive circulating cancer cells were found in all secondary HCC patients (9 / 9 patients, 100%) (Table 6).
[0270] Therefore, MVP (50.3%) or 63-D7 (72.3%) single-positive circulating cancer cells were EpCAM-negative and Vimentin-negative and predominantly expressed in all secondary HCC patients. Therefore, PTGFRN recognized by 63-D7 is a novel marker representing most circulating cancer cells in patients with hepatocellular carcinoma that show neither epithelial nor mesenchymal characteristics, and it is an excellent diagnostic marker observed in all patients with secondary metastatic / recurrent hepatocellular carcinoma.
[0271]
[0272] 10-4. Analysis of immune checkpoint molecules in 63-D7-positive blood cancer cells.
[0273] Numerous studies have established a strong correlation between B7-H3 expression and poor clinical outcomes in various cancers, including HCC. Since we experimentally confirmed that PTGFRN interacts with B7-H3 in HCC cells (Figures 11c and 11d), we analyzed the expression of PTGFRN, B7-H3, and other immunoregulatory molecules in circulating cancer cells using triple staining.
[0274] For triple staining of 63-D7, B7-H3, and immunomodulatory molecules, cells were adhered to poly-L-lysine-coated glass. After CD45-depleted cells were fixed, blocked, and reacted with anti-poly rabbit MVP antibody (Aviva bioscience), ULBP1 (Abcam), MICA / B (Bioss), and TGFβR1 (Atlas). They were then reacted with Alexa 568-conjugated anti-rabbit IgG (Thermo Fischer Scientific) or Alexa 594-conjugated mouse monoclonal PD-L1 (Biolegend), PD-L2 (Biolegend), or phycoerythrin-conjugated CD47 (Biolegend). The cells were then reacted with Dylight 650-conjugated anti-rabbit B7-H3 (Sinobiological, Beijing, China) and Dylight 488-conjugated 63-D7 antibody. Ca was added between each step. 2+ and Mg 2+ Cells were washed four times with PBS containing . Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI), and fluorescence signals were detected using a Leica TCS SP5 confocal microscope. The expression profiles of EMT and immune checkpoint markers in nucleated CTCs from secondary HCC patients by triple immunofluorescence staining are shown in Table 7 below.
[0275] MarkersPatients with marker-positive CTCs (%)Marker-positive CTCs(% marker / CTCs)MVP + 63-D7 + B7-H3 + 22 / 22 (100.0%)57 / 458 (12.4%)MVP + 63-D7 + B7-H3 - 20 / 22 (90.9%)54 / 458 (11.8%)MVP + 63-D7 - B7-H3 + 6 / 22 (27.3%)15 / 458 (3.3%)MVP + 63-D7 - B7-H3 - 0 / 22 (0%)0 / 458 (0%)MVP - 63-D7 + B7-H3 + 22 / 22 (100.0%)160 / 458 (34.9%)MVP - 63-D7 + B7-H3 - 22 / 22 (100.0%)77 / 458 (16.8%)MVP - 63-D7 - B7-H3 + 20 / 22 (90.9%)60 / 458 (13.1%)MVP- 63-D7- B7-H3- (DAPI only)18 / 22 (81.8%)35 / 458 (7.6%)MVP + / total PTGFRN + or B7-H3 + / total PTGFRN + 111 / 348 (31.9%) or 217 / 348 (62.4%)TGFβR1+ 63-D7 + B7-H3 + 18 / 18 (100.0%)140 / 787 (17.8%)TGFβR1+ 63-D7 + B7-H3 - 18 / 18 (100.0%)109 / 787 (13.9%)TGFβR1+ 63-D7 - B7-H3 +<h2 style=";text-align:left;direction:ltr">18 / 18 (100.0%)79 / 787 (10.0%)TGFβR1+ 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)54 / 787 (6.9%)TGFβR1-63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)139 / 787 (17.7%)TGFβR1- 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)93 / 787 (11.8%)TGFβR1-63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)108 / 787 (13.7%)TGFβR1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> (DAPI only)16 / 18 (88.9%)65 / 787 (8.3%)TGFβR1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> or B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 249 / 481 (51.8%) or 279 / 481 (58.0%),ULBP1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 1 / 14 (7.1%)1 / 404 (0.24%)ULBP1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 8 / 14 (57.1%) 8 / 404 (2.0%) ULBP1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 11 / 14 (78.6%)17 / 404 (4.2%)ULBP1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100%)26 / 404 (6.4%)ULBP1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)111 / 404 (27.5%)ULBP1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> -<h2 style=";text-align:left;direction:ltr">14 / 14 (100.0%)102 / 404 (25.2%)ULBP1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)99 / 404 (24.5%)ULBP1- 63-D7- B7-H3- (DAPI only)14 / 14 (100.0%)40 / 404 (9.9%)ULBP1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> or B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 9 / 222 (4.1%) or 112 / 222 (50.5%)MICA / B<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)116 / 675 (17.2%)MICA / B<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 16 / 18 (88.9%)26 / 675 (3.9%)MICA / B<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 17 / 18 (94.4%)29 / 675 (4.3%)MICA / B<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100%)33 / 675 (4.9%)MICA / B<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)151 / 675 (22.4%)MICA / B<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100.0%)116 / 675 (17.2%)MICA / B<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 18 / 18 (100%)142 / 675 (21.0%)MICA / B<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> (DAPI only)16 / 18 (88.9%)65 / 675 (9.6%)MICA / B<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> or B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 142 / 409 (34.7%) or 267 / 409 (65.3%)PD-L1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)114 / 950 (12.0%)PD-L1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 19 / 22 (86.4%)83 / 950 (8.7%)PD-L1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 20 / 22 (90.9%)80 / 950 (8.4%)PD-L1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)64 / 950 (6.7%)PD-L1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)176 / 950 (18.5%)PD-L1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)148 / 950 (15.6%)PD-L1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 21 / 22 (95.5%)208 / 950 (21.9%)PD-L1<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> (DAPI only)20 / 22 (90.9%)77 / 950 (8.1%)PD-L1<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> or B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 197 / 521 (37.8%) or 290 / 521 (55.7%)PD-L2<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 21 / 22 (95.5%)39 / 719 (5.4%)PD-L2<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 19 / 22 (86.4%)30 / 719 (4.2%)PD-L2<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 19 / 22 (86.4%)28 / 719 (3.9%)PD-L2<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)39 / 719 (5.4%)PD-L2<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)183 / 719 (25.5%)PD-L2<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100.0%)143 / 719 (19.9%)PD-L2<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 22 / 22 (100%)180 / 719 (25.0%)PD-L2<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> (DAPI only)20 / 22 (90.9%)77 / 719 (10.7%)PD-L2<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> or B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> / total PTGFRN<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 69 / 395 (17.5%) or 222 / 395 (56.2%)CD47<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)78 / 497 (15.7%)CD47<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)37 / 497 (7.4%)CD47<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)41 / 497 (8.2%)CD47<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> 63-D7<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> B7-H3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 14 / 14 (100.0%)35 / 497 (7.0%)CD47<h2 style=";text-align:left;direction:ltr"> -63-D7 + B7-H3 + 14 / 14 (100.0%)78 / 497 (15.7%)CD47 - 63-D7 + B7-H3 - 14 / 14 (100.0%)109 / 497 (21.9%)CD47 - 63-D7 - B7-H3 + 14 / 14 (100.0%)62 / 497 (12.5%)CD47 - 63-D7 - B7-H3 - (DAPI only)14 / 14 (100.0%)57 / 497 (11.5%)CD47 + / total PTGFRN + or B7-H3 + / total PTGFRN + 115 / 302 (38.1%) or 156 / 302 (51.7%)
[0276]
[0277] In a previous study, we reported that MVP is responsible for the survival, proliferation, migration, and invasion of HCC cells under stressful environments. Furthermore, B7-H3 is known to interact with MVP and promote cancer stem cell enrichment in breast cancer cells. Therefore, to determine the prevalence of PTGFRN-positive circulating cancer cells in patients with secondary hepatocellular carcinoma (HCCs) at the time of HCC metastasis and recurrence, circulating cancer cells were simultaneously stained with 63-D7, anti-B7-H3, and anti-MVP antibodies (Fig. 18b, Table 7). Approximately 32% (111 / 348) of the total PTGFRN-positive circulating cancer cells were MVP-positive, and approximately 62% (217 / 348) of the total PTGFRN-positive circulating cancer cells were B7-H3-positive. Therefore, a subset of PTGFRN-positive circulating cancer cells is likely to be associated with the roles of B7-H3 and MVP in cell survival, proliferation, migration, and invasion in the peripheral blood of secondary HCC patients.
[0278] Recent studies have shown that EMT confers metastatic potential, immunosuppressive potential, and cancer stemness to cancer cells. Furthermore, EMT can induce the expression of immunosuppressive molecules, such as PD-L1 and CD47, in cancer stem cells and circulating cancer cells. Approximately 53% of 63-D7-positive circulating cancer cells in patients with primary hepatocellular carcinoma (HCC) were EMT-phenotype circulating cancer cells, but the proportion decreased to 27.6% in patients with secondary HCC (Table 6). Instead, most 63-D7-positive circulating cancer cells (72.3%) in patients with secondary HCC were partial / intermediate phenotype circulating cancer cells (Table 6). Recent studies suggest that partial / intermediate phenotype cancer cells mediate tumor immune escape by evading immune cell cytotoxicity and polarizing immune cells toward an immunosuppressive phenotype. Therefore, 63-D7-positive circulating cancer cells with a partial / intermediate phenotype are expected to play an important role in patients with secondary hepatocellular carcinoma.
[0279] TGFβ / TGFβR1 signaling exerts multiple immunosuppressive effects in cancer stem cells. TGFβ is also required for the suppression of NK cell function. Furthermore, TGFβ / TGFβR1 signaling confers a high metastasis-initiating capacity of breast CSCs. TGFβ1 signaling also promotes T cell-mediated tumor evasion in colorectal cancer via increased B7-H3 expression. Therefore, although the number of EMT phenotype circulating cancer cells was reduced in PTGFRN-positive circulating cancer cells from secondary HCC patients, we investigated the extent to which TGFβR1 expression was positive in 63-D7-positive circulating cancer cells. When circulating cancer cells were stained with anti-TGFβR1, 63-D7, and anti-B7-H3 antibodies, all secondary HCC patients harbored TGFβR1-positive circulating cancer cells (Figure 19, Table 7). Detailed analysis revealed that 51.8% (249 / 481) of all PTGFRN-positive circulating cancer cells were TGFβR1-positive, and 58% (279 / 481) of all PTGFRN-positive circulating cancer cells were B7-H3-positive, suggesting that PTGFRN-positive circulating cancer cells likely have a TGFβR1- and B7-H3-mediated immunosuppressive phenotype.
[0280] To further investigate how PTGFRN-positive circulating cancer cells are associated with the host immune response in patients with secondary HCC, circulating cancer cells were simultaneously triple-stained with anti-ULBP1 / 63-D7 / anti-B7-H3 antibodies or anti-MICA / B / 63-D7 / anti-B7-H3 antibodies (Fig. 20a, Fig. 20b, Table 7).
[0281] ULBP1 and MICA / B are known as ligands for the activating receptor NKG2D of NK and CD8 T cells, and are molecules that promote immunity. In ULBP1 / 63-D7 / B7-H3 staining, 4.1% (9 / 222) of total PTGFRN-positive circulating tumor cells were ULBP1-positive in secondary HCC patients, whereas 50.5% (112 / 222) of total PTGFRN-positive circulating tumor cells were B7-H3-positive. In MICA / B / 63-D7 / B7-H3 staining, all patients (18 / 18) had MICA / B-positive circulating tumor cells. In patients with secondary HCC, 34.7% (142 / 409) of all PTGFRN-positive circulating cancer cells were MICA / B-positive, and 65.3% (267 / 409) of all PTGFRN-positive circulating cancer cells were B7-H3-positive. These results suggest that although secondary circulating cancer cells do express some immunoactivating molecules, such as ULBP1 (4.1%) or MICA / B (34.7%), most of them preferentially express B7-H3 (65.3%), a known immune checkpoint regulatory molecule.
[0282] PD-L1 and PD-L2 are well-known ligands for the immunosuppressive receptor PD-1 on NK and CD8 T cells. Therefore, circulating cancer cells were simultaneously triple-stained with anti-PD-L1 / 63-D7 / anti-B7-H3 antibodies or anti-PD-L2 / 63-D7 / anti-B7-H3 antibodies, respectively (Fig. 21a, Fig. 21b, Table 7).
[0283] In PD-L1 / 63-D7 / B7-H3 staining, 37.8% (197 / 521) of the total PTGFRN-positive circulating cancer cells in patients with secondary hepatocellular carcinoma were PD-L1 positive, and 55.7% (290 / 521) of the total PTGFRN were B7-H3 positive. In PD-L2 / 63-D7 / B7-H3 staining, 17.5% (69 / 395) of the total PTGFRN-positive circulating cancer cells in patients with secondary hepatocellular carcinoma were PD-L2 positive, and 56.2% (222 / 395) of the total PTGFRN were B7-H3 positive (Fig. 21a, Fig. 21b, Table 7). Meanwhile, all patients (22 / 22) had PD-L1 or PD-L2-positive circulating cancer cells.
[0284] Finally, we investigated whether PTGFRN-positive circulating tumor cells were associated with CD47, as CD47 is a "don't eat me" signal for macrophages and inhibits phagocytic innate immune surveillance (Matlung, Szilagyi et al. 2017). In patients with secondary hepatocellular carcinoma, 38.1% (115 / 302) of the total PTGFRN-positive circulating tumor cells were CD47-positive, and 51.7% (156 / 302) were B7-H3-positive, according to CD47 / 63-D7 / B7-H3 staining (Figure 22, Table 7). All patients (14 / 14) had CD47-positive circulating tumor cells.
[0285] Although immunostimulatory receptors such as ULBP1 (4.1%) and MICA / B (34.7%) were detected in PTGFRN-positive circulating cancer cells, immune checkpoint regulatory molecules such as TFGβR1 (51.8%), PD-L1 (37.8%), PD-L2 (17.5%), CD47 (38.1%), and B7-H3 (50.5-65.3%) were more prevalently detected in PTGFRN-positive circulating cancer cells from secondary HCC patients. In particular, B7-H3 was predominantly expressed (average 57.6%) in all PTGFRN-positive circulating cancer cells. Therefore, these results suggest that PTGFRN is responsible for immune evasion of circulating cancer cells in secondary HCC patients, and its expression closely associates with immunosuppressive receptors, playing a role in immune evasion. These results suggest that PTGFRN recognized by the 63-D7 antibody in circulating cancer cells may serve as an excellent diagnostic marker for indicating the stage or progression of liver cancer.
[0286]
[0287] Example 11. Analysis of the monoclonal antibody 63-D7 gene and amino acid.
[0288] 5 x 10 of vigorously growing hybridoma 63-D7 cells 6After harvesting the dogs by centrifugation, the animals were washed twice with cold PBS, and total RNA was extracted using RNAiso plus reagent (TaKaRa, Otsu, Japan) according to the manufacturer's protocol. The amount of RNA was quantified by measuring the A260 of total RNA using a Nanodrop. 1 unit of DNase I (TaKaRa) per 1 μg of total RNA was added and incubated at 37°C for 30 minutes to remove residual DNA. 1 μl of 50 mM EDTA was added and incubated at 65°C for 10 minutes to inactivate DNase I and denature total RNA. A reverse transcription-polymerase chain reaction (RT) mixture was prepared using total RNA and Prime Script RT reagent Kit (TaKaRa), and cDNA was synthesized according to the manufacturer's protocol. In order to clone heavy chains using synthesized cDNA, 25 pmoles of an oligonucleotide having the polymerase chain reaction primer sequence 5'-gga gtc gac ATA GAC AGA TGG GGG TGT CGT TTT GGC-3' (SEQ ID NO: 20) corresponding to the IgG1 constant region, 25 pmoles of an oligonucleotide having the base sequence 5'MH1 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TC-3' (SEQ ID NO: 21) corresponding to the N-terminus of the heavy chain antibody variable region, and 25 pmoles of an oligonucleotide 5'MH2 5'-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TCW GG-3' (SEQ ID NO: 22) corresponding to the heavy chain antibody variable region were added to create a chain polymerization reaction mixture. For light chain cloning, the oligonucleotide 5'-ggt gtc gac GGA TAC AGT TGG TGC AGC ATC-3' (SEQ ID NO: 23) primer corresponding to the kappa chain constant region and the oligonucleotide 5'MK 5'-cgg aag ctt GAY ATT GTG MTS ACM CAR WCT MCA-3' (SEQ ID NO: 24) primer corresponding to the N-terminus of the kappa chain variable region were used.For efficient cloning of polymerase chain reaction products, EcoRI restriction sites were added to the 5'-primer terminus and SalI restriction sites were added to the 3'-primer terminus for the heavy chain. For the light chain, HindIII restriction sites were added to the 5'-primer terminus and SalI restriction sites were added to the 3'-primer terminus. After mixing the polymerase reaction primers of the heavy or light chain and 1 unit of i-pfu DNA Polymerase (iNtRON Biotechnology, Seoul, Korea), the reaction was performed once at 95 °C for 5 minutes, followed by 30 cycles of 95 °C for 1 minute, 35 °C for 1 minute, and 72 °C for 1 minute. As a result, amplified DNA was obtained at a position corresponding to approximately 400 bp, which is estimated to be a DNA fragment corresponding to the heavy chain variable region, and approximately 390 bp, which is estimated to be a DNA fragment corresponding to the light chain variable region.
[0289] To clone the amplified 63-D7 gene, the heavy chain of the polymerase chain reaction product was first treated with EcoRI and SalI, and the light chain was treated with HindIII and SalI, and then developed on a 1.0% (w / v) agarose gel. DNA corresponding to approximately 400 bp and 390 bp was isolated using the FavorPrep GEL PCR Purification Kit (Favorgen, Pingtung, Taiwan). The vector pBluescript KS+, into which the heavy chain gene was cloned, was treated with EcoRI and SalI, and the vector pBluescript KS+, into which the light chain gene was cloned, was treated with HindIII and SalI, and then isolated using the FavorPrep GEL PCR Purification Kit. These two DNAs were ligated with T4 DNA ligase (New England Biolab, Massachusetts, USA) and transformed into Escherichia coli DH5α using the CaCl2 method. For DNA sequence analysis of antibody genes, the above-mentioned multiple clones were cultured overnight in 3 ml of LB medium containing 100 μg / ml of ampicillin. Plasmid DNA was isolated using a DNA-Spin plasmid mini prep kit (Intron, Korea) according to the manufacturer's protocol. E. coli clones with DNA inserts of approximately 400 bp in size for the heavy chain and E. coli clones with DNA inserts of approximately 390 bp in size for the light chain were selected. The base sequence of each DNA insert was confirmed by nucleotide sequencing (Bionics, Seoul, Korea).
[0290] After translating the base sequences of the heavy and light chain DNA into amino acids and organizing the antigen recognition determining sites according to the antibody structure using Kabat numbering, the heavy chain corresponded to subgroup ⅡB (Figure 23) and the light chain corresponded to subgroup V (Figure 24). The antigen binding sites, CDRs 1, 2, and 3, are indicated in bold in each sequence. Comparison of the amino acid sequences of the antibodies using BLAST confirmed that 63-D7 is a novel antibody with no known history.
Claims
1. An anti-PTGFRN monoclonal antibody comprising a heavy chain variable region comprising HCDR1 consisting of the amino acid sequence of SEQ ID NO: 3, HCDR2 consisting of the amino acid sequence of SEQ ID NO: 4, and HCDR3 consisting of the amino acid sequence of SEQ ID NO: 5; and a light chain variable region comprising LCDR1 consisting of the amino acid sequence of SEQ ID NO: 6, LCDR2 consisting of the amino acid sequence of SEQ ID NO: 7, and LCDR3 consisting of the amino acid sequence of SEQ ID NO:
8.
2. In claim 1, the heavy chain variable region is an anti-PTGFRN monoclonal antibody comprising the amino acid sequence of sequence number 1.
3. In claim 1, the light chain variable region is an anti-PTGFRN monoclonal antibody comprising the amino acid sequence of sequence number 2.
4. An antibody-drug conjugate in which a drug is conjugated to the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
5. A pharmaceutical composition for treating or preventing cancer comprising the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
6. A pharmaceutical composition for treating or preventing cancer, wherein the cancer in claim 5 is selected from the group consisting of brain and spinal tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophageal cancer, stomach cancer, colon cancer, liver cancer, thyroid cancer, pancreatic cancer, biliary tract cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, germ cell tumor, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma, neuroblastoma, glioblastoma, and skin cancer.
7. A hybridoma producing the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
8. A composition for detecting PTGFRN comprising the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
9. A method for providing information for diagnosing cancer, comprising the step of treating a sample isolated from an individual with an anti-PTGFRN monoclonal antibody according to any one of claims 1 to 3.
10. A method for providing information necessary for determining the level of blood cancer cells, comprising the step of treating a sample isolated from an individual with an anti-PTGFRN monoclonal antibody according to any one of claims 1 to 3.
11. A method for providing information necessary for determining the level of blood cancer cells, wherein the sample is selected from the group consisting of blood, plasma, bone marrow fluid, lymph, saliva, tears, urine, mucosal fluid, and amniotic fluid, according to claim 10.
12. A method for providing information necessary for determining the level of cancer cells in blood, further comprising a step of treating the sample with a substance that specifically binds to EpCAM according to claim 10.
13. A method for providing information necessary for determining the level of cancer cells in blood, wherein the substance that specifically binds to EpCAM according to claim 12 is an anti-EpCAM antibody or an antigen-binding fragment thereof.
14. A method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells in claim 10 are blood cancer cells undergoing epithelial-mesenchymal transition or undergoing epithelial-mesenchymal transition.
15. A method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells according to claim 10 are not epithelial cells or mesenchymal cells.
16. A method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells in claim 10 are blood cancer cells in the blood of a patient with liver cancer, lung cancer, colon cancer, thyroid cancer, pancreatic cancer, malignant melanoma, breast cancer, neuroblastoma, or glioblastoma.
17. A method for providing information necessary for determining the level of blood cancer cells, wherein the blood cancer cells further express B7-H3 (CD276) protein according to claim 10.
18. A method for providing information necessary for predicting the prognosis of cancer metastasis, comprising the step of detecting PTGFRN by treating a sample isolated from an individual with the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
19. A method for providing information necessary for predicting the prognosis of cancer metastasis, further comprising a step of providing information that if the level of the detected PTGFRN is higher than that of the control group, the prognosis of cancer metastasis is worse than that of the control group.
20. A method for screening the efficacy of an anticancer drug, comprising the step of detecting PTGFRN by treating a sample isolated from a patient administered an anticancer drug with the anti-PTGFRN monoclonal antibody of any one of claims 1 to 3.
21. A method for screening the efficacy of an anticancer drug, further comprising a step of predicting that the anticancer drug has a better anti-cancer metastasis inhibition efficacy than the control group if the level of the detected PTGFRN is lower than that of the control group in claim 20.
22. A composition for detecting blood cancer cells, comprising a substance that binds to PTGFRN.
Citation Information
Patent Citations
System for concrete crack detection using 2D and 3D image
KR102449124B1
Novel antibody-drug conjugates and the use of same in therapy
US20190365914A1
Monoclonal antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
US20210188972A1
